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resumo 
 
 
Este relatório descreve as actividades desenvolvidas durante o meu estágio 
curricular como assistente de gestor de projecto, no Centro de Coimbra de 
Coordenação de Investigação Clínica, 4C, uma academic contract reseach 
organisation (aCRO). É um centro de investigação pertencente à Associação 
para Investigação Biomédica e Inovação em Luz e Imagem, AIBILI. 
O estágio decorreu entre 8 de outubro de 2012 a 7 de junho de 2013 e teve 
como principal objectivo adquirir ferramentas de trabalho e competências na 
área de gestão de projecto que me possibilitem integrar o mercado actual de 
trabalho. 
Além dos serviços que presta à indústria farmacêutica, o 4C atua como uma 
aCRO apoiando o desenvolvimento e a coordenação de Ensaios Clínicos da 
Iniciativa do Investigador (IDCTs). Assim, dos 11 projetos de investigação em 
que estive envolvida, 10 foram IDCTs. Neste documento é apresentada uma 
caracterização sobre o estado da arte dos IDCTs. 
Como assistente de gestor de projectos num centro de investigação clínica 
pude participar em diversas actividades de diferentes âmbitos: elaboração de 
documentos de estudo, planeamento e validação de um caderno de recolha de 
dados (CRD) electrónico, introdução e validação de dados, avaliação da 
exequibilidade de centros de ensaio, gestão de dados, gestão de estudos 
clínicos e arquivo e gestão de documentação de estudos clínicos. Tive ainda a 
oportunidade de apoiar o monitor de estudo em actividades relacionadas com 
o final da fase clínica de um ensaio. 
Além das tarefas desempenhadas, recebi treino genérico na área de 
especialidade da AIBILI – oftalmologia. Entre formações e seminários, tive a 
oportunidade de participar num curso sobre a degenerescência da mácula 
relacionada com a idade e angiogénese, de 15 horas. 
O ambiente multidisciplinar das actividades realizadas no 4C permitiram-me 
adquirir um conhecimento mais abrangente sobre o ciclo de vida de um projeto 
de investigação. Especificamente, a participação em actividades de desenho, 
implementação, condução e coordenação de um projecto de investigação 
clínica permitiu-me valorizar o papel fundamental de um gestor de projecto 
nestes processos. 
A experiencia adquirida neste estágio curricular foi muito enriquecedora. 
Através de uma participação ativa nas diversas actividades praticadas pelo 4C, 
adquiri competências pessoais e profissionais que no futuro irão possibilitar 
trabalhar nesta área. O estágio também me permitiu integrar conhecimentos 
adquiridos no Mestrado em Biomedicina Farmacêutica nas diversas 
actividades de investigação clínica realizadas. 
Termino este estágio com a motivação e certeza que gostaria de integrar o 
mercado de trabalho na área de gestão de projecto. 
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abstract 
 
 
 
 
 
This report describes my curricular internship activities performed as a project 
manager assistant at the Coimbra Coordinating Centre for Clinical Research, 
4C, an academic Contract Research Organisation (aCRO). It is a Research 
Centre pertaining to Association for Innovation and Biomedical Research on 
Light and Image, AIBILI. 
The internship occurred from 8th October 2012 to 7th June 2013 and had as a 
major objective to acquire specific working tools and competencies in the 
project management area that enables me to integrate the current labor 
market. 
Besides providing services to pharmaceutical industry, as an aCRO 4C 
supports the development and coordination of Investigator-Driven Clinical Trials 
(IDCTs). Due to this fact, of the 11 clinical projects that I was involved, 10 were 
IDCTs. In this document, a characterization of the state of the art on IDCTs is 
presented.   
As a project manager assistant in a clinical research coordinating centre I could 
participate in several activities from different contexts: study documents 
elaboration, planning and validation of an electronic case report form (eCRF), 
data entry and validation, feasibility assessment, study and data management 
and archiving and managing clinical trial documentation. In addition, I could 
assist the study monitor in end of clinical-trial related activities.  
Additionally to the on-the-job activities, I receive a generic training concerning 
the area of expertise of AIBILI – ophthalmology. Between training sessions and 
workshops, I had the opportunity to attend a training course of 15 hours 
regarding age-related macular degeneration and angiogenesis. 
The multidisciplinary framework of the activities performed at 4C has enabled 
me to acquire a more comprehensive knowledge of a clinical project’s lifecycle. 
Particularly, participating in the design, implementation, conduction and 
coordination of a clinical research project enabled me to understand the central 
role of a project manager in a clinical study. 
The experience taken from this curricular internship was very enriching to me. 
As I accomplish to develop an active participation through the activities carried 
out by 4C, I developed personal skills and acquired professional competencies 
which, in the future, allow me to work in this area. It was also possible to 
integrate into clinical research activities the background knowledge from the 
Master course in Pharmaceutical Medicine.  
I complete this curricular training with the motivation and certain that I would 
like to work as a project manager in the future. 
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1 
Introduction  
 
From 8
th
 October 2012 to 7
th
 June 2013 I had the opportunity to complete my Master’s Degree in 
Pharmaceutical Medicine attending a curricular internship at Coimbra Coordinating Centre for 
Clinical Research (4C), an academic contract research organisation (aCRO) of Association for 
Innovation and Biomedical Research on Light and Image (AIBILI). 
My training report is the compilation of all activities performed in 4C. This report is organised in 
five chapters. The first chapter is an introduction to contextualise the training and to present its 
structure that includes a characterisation of the host institution, my training objectives and a 
description about the state-of-the-art on Investigator-Driven Clinical Trials (IDCTs) and the 
importance of aCROs. During my training, most of all clinical research projects that I was involved 
were IDCTs. Due to this fact, the state-of-the-art will address IDCTs by: 
• Introducing some definitions and particularities of IDCTs,  
• Describing the necessity for conducting IDCTs, enunciating the advantages of academic 
partnerships; 
• Describing the current European and Portuguese status of activity of investigator-initiated 
clinical research; 
• Describing the current obstacles needed to overpass to conduct IDCTs in Europe.   
 
The second chapter is the generic training where I described the training sessions, workshops and 
a training course attended at AIBILI. The specific training refers to the activities performed at 4C, 
and is the third chapter. The final two chapters refer to a discussion of my training experience and 
finally some conclusions are drawn from this training period. 
This training report will also include two annexes representing an important task carried out in 
the specific training, responsible for the implementation of a new tool to manage and send 
questionnaires. These are a comparative document concerning Lime Survey and Monkey Survey 
characteristics and a Lime Survey user manual.  
For the purpose of this training report, the term IDCT includes all clinical trials initiated by 
academic and non-academic researchers with non-commercial interests. 
 
 
2 
1.1. Vision of the Host Institution 
 
AIBILI is a private, non-profit, Research Technology Organization (RTO). The core mission of this 
type of organizations is to explore science and technology in the service of innovation, to improve 
quality of life and built economic competitiveness. RTOs bring together key players across the 
whole innovation chain, from basic to technological research, from product and process 
development to prototyping and demonstration. RTOs are generally non-profit organizations in 
which revenues from dissemination and deployment are re-employed to fund new innovation 
cycles (1, 2). 
In an historical context, AIBILI was established to support technology transfer between academic 
institutions and the industry and to give patients access to the most recent results of biomedical 
research. It was founded in 1989, initially with the support of the Ministry of Economy’s through 
the program Programa Específico de Desenvolvimento da Indústria Portuguesa. It is located at the 
Health Campus of Coimbra University since 1994 (1, 3).  
Since 2004, AIBILI is certified by International Organisation for standardisation (ISO) 9001 
standard and clinical trials are performed in accordance with International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 
Good Clinical Practice Guidelines (ICH-GCP) and the pharmacology studies are also developed in 
compliance with the Organisation for Economic Co-operation and Development (OECD) Principles 
of Good Laboratory Practice (GLP) (1). 
AIBILI is organized in Research Centres and Structural Units. The Research Centres are: 4C, 
European Vision Institute Clinical Research Network (EVICR.net), Coimbra Ophthalmology Reading 
Centre (CORC), Health Technology Assessment and Drug Research (CHAD), Clinical Trial Centre 
(CEC) and Centre of New Technologies for Medicine (CNTM). The Structural Units are: Quality 
Management, Administrative Services, Translational Research and Technology Transfer and 
Information Technology. Table 1 and Table 2 present a brief description of the main activities 
performed at each Research Centre and Supporting Unit (1, 4). 
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Table 1 – Research Centres of AIBILI and their main activities in 2013 (1, 4). 
 
Research Centre Main activity(ies) 
4C Structure to support the development and coordination of Investigator-
Driven and Industry-Sponsored Clinical Trials. 4C is also the coordinating 
centre of the EVICR.net. 
 
 EVICR.net European network for clinical research in ophthalmology, created in 2010. 
At present, EVICR.net has 79 members from 16 European Countries. 
 
CORC Structure for grading ophthalmological images such as CFP and OCT images 
of the retina and functional evaluations of retina using multifocal 
electroretinogram.  
 
CHAD Evaluates medicines and other medical products for market access 
purposes, aiming at financing and reimbursement, performs 
pharmacovigilance and bioequivalence studies for generic drugs approval 
and drug safety monitoring. 
 
CEC Performs clinical trials with special emphasis on ophthalmology and 
neurology. 
 
CNTM Develops new medical diagnostic techniques with special emphasis on the 
area of eye fundus imaging. 
CFP – Colour Fundus Photography; OCT – Optical Coherence Tomography 
Table 2 – Structural Units of AIBILI and their main activities in 2013 (1, 4). 
 
Structural Unit Main Activity (ies) 
Quality Management Assure that quality management system is maintained effective 
and efficient, permitting a continual improvement and that the 
services provided by AIBILI are valid and reliable.  
 
Administrative Services Management of AIBILI and all related administrative tasks, 
including finances, human resources management and 
maintenance of the infrastructure. 
 
Translational Research and 
Technology Transfer 
Management of external contracts and partnerships, acquisition 
of external funding, promotion of AIBILI as well as the activities 
and services of its Research Centres. 
 
Information Technology 
 
 
 
 
Guarantees the safety and integrity of the data and images 
collected. Management and maintenance of the electronic 
medical records of the CEC that is daily used to collect patient 
data and the platform of CORC used to exchange data and 
images. This Structural Unit is under the responsibility of CNTM. 
 
The organogram of AIBILI is presented in Figure 1. The Board of Directors is constituted by the 
President José Cunha-Vaz, Vice-President Joaquim Murta, Tice Macedo representing BIAL – 
Portela & Cª, SA, João Silveira Botelho representing Champalimaud Foundation, Conceição Lobo 
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representing José Cotta – EMS, SA, Cristina Morgado representing Novartis Farma and José Aleixo 
Dias representing Pfizer Laboratories (1).  
 
Figure 1 – Organisational structure of AIBILI with the responsible of each Research Centre and Structural Unit (1). CEO 
– Chief Executive Officer. 
 
Concerning AIBILI’s financial status, its activity is mainly supported by services to industry. 
Examples of actual industry clients are Novartis, Bayer, Pfizer, Sanofi-Aventis, between others. 
Public funding is present essentially in Research and Development (R&D) projects financed by 
Portuguese Foundation for Science and Technology as well as the European Commission. The 
financial evolution of AIBILI in the last five years is represented by the Figure 2 (5). 
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Figure 2 – Evolution of  AIBILI funding in the last five years (5). 
 
Regarding human resources, AIBILI has a permanent staff of 42 individuals including medical 
doctors, researchers, engineers, pharmacologists, technicians, trial and project managers, study 
coordinators and administrative personnel. Another 64 individuals collaborate regularly on a part-
time basis being involved mainly in research activities (1).  
By the end of 2012, AIBILI counts 93 ongoing studies, services, projects and contracts from the 
different Research Centres. Between 2011 and 2012, 106 scientific articles were published (1). 
AIBILI is certified by ISO 9001 for the following activities (1): 
• Research and development in new technologies for medicine with particular emphasis in 
the areas of imaging, optics and light;  
• Preclinical studies of new molecules of potential medical use; 
• Performance of clinical trials;  
• Planning, coordination, execution and monitoring of clinical research activities;  
• Health technology assessment.  
 
The main objectives of AIBILI are (3): 
• To assume a leading role as an aCRO, supporting IDCTs, either at a national and 
international levels; 
• To coordinate and promote the EVICR.net; 
• To launch in the market innovative diagnostic products in ophthalmology; 
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• To maintain the Quality Management System and meet the requirements specified in the 
implemented standards; 
• To assure a sustained growth based on solid financial conditions.  
 
The main strategies of this aCRO are innovation and internationalization, assuming a leading role 
in translational research in vision and imaging and bringing together academic institutions and 
industry (1, 3). 
The 4C Research Centre is an aCRO where I perform my internship. 4C supports the development 
and coordination of Investigator-Driven and Industry-Sponsored Clinical Trials by providing the 
services listed in  
Table 3. This Research Centre has the support of the Champalimaud Foundation as the core unit 
of AIBILI for C-Tracer (Champalimaud Translational Centre for Eye Research) activities (6).  
 
Table 3 – Services provided by 4C through a clinical research project’s lifecycle (6). 
 
           Pre-Study Services                           In-Study Services       Post-Study Services 
Study Design 
Protocol Design 
Informed Consent Form 
SOP Development 
Submissions to the RA 
Contracts Elaboration 
Study Management and Coordination 
Monitoring/ Auditing 
Data Management 
Periodical Reports to the Sponsor and/or RA 
Pharmacovigilance 
Data Validation 
Data Analysis 
Final Study Reports 
Regulatory Reports 
Scientific Publication 
RA – Regulatory Authorities; SOP – Standard Operational Procedure  
 
4C is currently staffed by an executive director, four medical consultants, six project/clinical trial 
managers, two information technology and one administrative assistant. The Medical Consultants 
involved in the Clinical Coordination of research projects are José Cunha-Vaz, Conceição Lobo, 
Rufino Silva and Joaquim Murta. The Figure 3 represents 4C organogram (1, 4). 
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Figure 3  - Organizational flowchart of 4C (6). 
 
Currently 4C is conducting 12 IDCTs and two Industry-Sponsored Clinical Trials. Table 4 specifies 
which of the studies that are undertaking are in a national or multinational (performed in at least 
two countries) level (1). 
 
Table 4 – Current projects undertaking by 4C for clinical trial support (1). 
 
Clinical Trial Multinational National 
Investigator-Driven  RET-2010-02 
EUROCONDOR 
C-Tracer Project nº 1 
PROTEUS 
Vitamin D3 – Omega 3 
Epidemiological study of AMD incidence 
Life style and food habits in population aged >55 
Macugen vs PRP in Proliferative Diabetic Retinopathy 
Lucentis vs PRP in Proliferative Diabetic Retinopathy 
DIAMARKER 
Diabetic Retinopathy Phenotypes 
Genotypes/ Phenotypes in Nonproliferative Diabetic       
Retinopathy 
Industry-Sponsored POLARIS Pharmacokinetic assessment 
AMD - Age-Related Macular Degeneration 
 
1.2. Training objectives 
 
The general objective of my curricular training was to consolidate the knowledge and tools 
acquired in the Biomedical Sciences Degree and the Master’s Course in Pharmaceutical Medicine, 
through the experience gathered from working as a project manager assistant  in an institution 
dedicated to the development and testing of new products or new therapeutic approach for 
medical therapy. 
More specifically, the objectives that I established to manage my curricular internship were: 
• Primary objectives: 
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o To develop an active participation as a project manager assistant through 
different activities and tasks carried out in an coordinating centre for clinical 
research; 
o To obtain specific working tools and techniques through the application of the 
skills already acquired and with the experience of senior professionals; 
o To acquire a multidisciplinary experience to develop pharmaceutical research 
activities that enables me to integrate the current labour market; 
o To apply and complement the theoretical background acquired during the first 
year of my Master Course and Biomedical Sciences Degree. 
 
• Secondary objectives: 
o To improve my social skills: communicate and transmit ideas, work as a team 
member, manage time by establishing priorities; 
o To improve my ability to analyse information critically and solve problems; 
o To gain autonomy in follow-up activities involved in an IDCT management;  
o To improve my medical writing skills by the support provided in the 
elaboration of study documents; 
o To demonstrate motivation and learning skills through the application of the 
knowledge gathered in 4C in my daily activities; 
o To acquire a comprehensive understanding of a clinical research project’s 
lifecycle; 
o To know the main diagnostic ophthalmologic exams and the diseases - Age-
Related Macular Degeneration (AMD)  and diabetic retinopathy (DR) – and 
their pathological processes and current therapeutics; 
o To understand the multidisciplinary framework of a clinical research 
coordinating centre and the specificities of an IDCT; 
o To know the structure, function mode and the main activities carried out by 
AIBILI’s Research Centres, with special emphasis on 4C. 
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1.3. State-of-the-Art 
 
Clinical trials are mainly conducted by the pharmaceutical industry in order to generate data on 
the safety and efficacy of medicinal products they are developing. There is however an increasing 
interest by non-industry actors (academics, foundations, hospitals and research-networks) (7). 
According to ICH-GCP, the sponsor is an individual, a company, an institution or organisation 
which takes responsibility for the initiation, management and/ or financing of a clinical trial (8). In 
IDCTs the sponsor is one investigator (sponsor-investigator) who both initiates and conducts the 
clinical study. This person is also responsible for the administration, dispense and usage of the 
investigational product to a trial subject (9). IDCTs are aimed at acquiring scientific knowledge and 
evidence to improve patient care. Such studies deal with potential diagnostic and therapeutic 
innovations that do not attract or could even be against commercial interest. They form a key part 
of patient-oriented clinical research and create the basis for continually improve patient care.  
Typical examples are proof-of-concept studies, studies on orphan diseases, comparison of 
diagnostic or therapeutic interventions, surgical therapies or novel indications for registered drugs 
(10). These trials provide the evidence needed for establishing treatment recommendations and 
ultimately guaranteeing the proper use of public healthcare resources. In addition, they speed up 
access to different treatments and maintain leadership and competitiveness by constantly 
encourage the design and conduction of more clinical research (10). 
From the perspective of the pharmaceutical company, the central aim of supporting IDCTs is to 
collect additional safety data and information that could be used to support new indications or be 
included as part of the dossier for licensure. Investigator’s interest in translational science 
dovetails with industry’s desire to bring new products to market. IDCTs usually have greater 
interest in niche indications rather than company-sponsored ones which focus on the 
commercialization at large markets. Conclusions obtained from independent research might be 
hypothesis-generating while pharmaceutical industry focus medicine’s licensing on safety rather 
than efficacy (especially if the product is only marginally efficacious). Concerning the conduction 
of an IDCT, the companies that provide the medicine must oversee the safety aspects and review 
any publications. Additionally, the compliance with ICH-GCP and suitable of capacities, facilities 
and procedures must be verified in technical and scientific standpoints. In addition the company 
has access to a complete safety database where the quality output is ensured (11). Table 5 
highlights some key differences between IDCTs and company-sponsored trials (11). 
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Table 5 – Differentiating aspects of typical IDCTs and company-sponsored trials. Adapted from (11) 
 
Aspects IDCT Company-sponsored trial 
Primary purpose Scientific research intended to publication or 
search for additional funding. 
To compare efficacy of drugs from different 
marketing authorisation holders. 
 
Regulatory submission of a product 
intended to large markets In order to 
generate financial outcomes. 
 
Funding 
Mechanism 
Different departments in a pharmaceutical 
company. 
 
R&D budgets inside the company. 
Study Conduct Conduction of the clinical study must follow 
ICH-GCP, regulatory and quality guidelines. 
The clinical study must follow 
regulatory guidelines, company SOPs 
and ICH-GCP. 
SOP – Standard Operational Procedure 
With the demand to bring innovative therapeutics to patients many companies realised that they 
need to look beyond their own walls for innovation (12). The increasing in R&D investment, drug 
failures and patents expirations are driving pharmaceutical companies to seek a new collaborative 
model to stimulate innovation. The idea that the next new approach might not come from 
internal research has led many companies to shift their R&D expenditures externally through 
collaborations with academia. Companies start to seek the knowledge where it is generated – 
through contribute of independent investigators (12). An important aim for both types of 
organisations is to close the gap between basic and clinical research, thereby allowing for a more 
evidence and outcomes-based approach to therapeutic development. Such approach will allow 
collaborative teams to work together to identify what the innovation gaps are in the development 
of new therapies, what needs to be accomplished and whose contributions are more valuable 
(12). In addition, Academic Medical Centres (AMCs), including both health sciences schools and 
health systems are important partners in clinical research (12). AMCs train future generations of 
physicians, pharmacists, nurses and other professionals that contribute to the whole clinical 
research project’s lifecycle. 
Pharmaceuticals companies may provide support to investigators through various mechanisms 
(giving financial support, providing study medication). The clinical researcher, as the sponsor-
investigator, assumes responsibility for designing the study; writing the protocol; monitoring the 
study; managing, analyzing and reporting the data; indemnifying investigators and trial subjects 
and selecting study personnel. In this context, clinical coordinating centres, acting as CROs, 
support the sponsor-investigator in all this clinical tasks (11, 12). Table 6 presents industry – 
investigator relationship models, its advantages and disadvantages, based on interviews with 
some of the leading life-sciences companies and the academic and non-academic researchers 
with whom they work (12). 
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Table 6 – Principal models for industry-investigator partnerships. Reproduced with authorisation (12).  
 
Model Definition Advantages Innovation disadvantages 
One company – one investigator A company forms a relationship with an 
investigator by providing funding for research. 
Provides a starting point for establishing a 
productive relationship. 
Does not explicitly encourage and often 
restricts communication with other 
investigators or companies that might bring 
value to the research; dilution of research 
effort. 
 
One company – one university A company develops a master agreement with a 
university and provides resources for a number of 
research projects with a single university. 
Better leverage of an existing relationship; 
master agreements streamline process of 
initiating new collaborations. 
Might be limited to capabilities and expertise 
of a single university; working with one 
company might limit the scope of the research; 
university is seen as extension of the company. 
 
One company supports a university 
consortium 
A company builds a consortium of several 
universities that focus on a specific topic. 
Universities share and leverage their joint 
knowledge and the company funds a broader 
scope of research. 
 
Limited interaction with a single company will 
not address industry-wide obstacles. 
One company supports a university 
institute 
One or more companies give a large donation to 
fund an existing institute or to establish a new 
institute at a university. 
The company has access to network of 
investigators and universities receive funding 
to support its research in a specific area. 
 
Researchers are often asked to keep resources 
and information around a project proprietary. 
Industry consortium (pre- or 
noncompetitive) 
The consortia could be structured to include many 
companies with one AMC, or conceivably many 
companies with multiple AMCs. 
Ability to effectively resource and address 
important but noncompetitive innovation 
challenges (for example, biomarkers). 
Agenda might be dominated by individual 
company contributors and could erode 
perception of meritocracy; companies and 
AMCs will need to find ways to profit from their 
activities to sustain participation. 
 
Competition A company invests in multiple investigators to 
research the same topic; the team to achieve the 
goal first receives funds for the next phase. 
The company engages multiple parties to focus 
on its problems. 
Researchers cannot share resources or 
information with other universities; the team 
that finishes first might not be the best one to 
continue the project. 
 
Venture capital investment A company provides several experts with seed 
money to start a company; milestones are 
established. 
May foster more rapid commercialization. Researchers sever their academic ties, thereby 
forfeiting a major source of information and 
ideas. 
 
Free-for-service The university provides a unique service to the 
company. 
Investigator can apply technology to real-world 
problems and receive funding; company has 
access to commercially unavailable technology. 
The researchers feel like “hired help” rather 
than partners; defining the challenge limits the 
value the university can provide. 
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The IDCT activity is quite different in Portugal than in Europe. Considering the number of clinical 
trials registered in the European Union Drug Regulating Authorities Clinical Trials (EudraCT) 
database from 2004 to 2013 (Table 7) the percentage of IDCTs, besides being constant, remains 
over time much lower than the commercial ones. The EudraCT number must be attributed to all 
interventional clinical trials with at least with one site in the European Union (EU). It is included on 
all Clinical Trial Applications (CTAs) within the European Community. The database went into 
operation on 1
st
 May 2004 and has been established in accordance with the Clinical Trial Directive 
2001/20/EC (13).  The statistics presented were taken from the database on 1
st
 March 2013 (14, 
15). 
From 2004 to 2008 there was an increase in the number of CTAs with a maximum of 9334 EudraCt 
numbers issued in 2008. In 2009, there was a significant decrease of EudraCT numbers issued, 
reaching up then a relatively constant number in the following years. Besides of these variations, 
the percentages of Investigator-Driven and industry-Sponsored Clinical Trials had sensibly remain 
the same over time (14, 15). 
 
Table 7 – Number of EudraCT numbers issued per sponsor type, per year  (14, 15). 
 
Year   2004 2005 2006 2007 2008 2009 2010 2011 2012 2013* 
Total of EudraCT  
Number issued in 
4613 6214 7214 7987 9334 6441 5914 6011 5399 981 
Clinical 
Trials 
recorded 
by 
sponsor 
type (%) 
Commercial 5096 
(82%) 
5844 
(81%) 
6390 
(80%) 
7420 
(79.5%) 
5089 
(79%) 
4672 
(79%) 
4749 
(79%) 
4265 
(79%) 
775 
(79%) 
Non-commercial 1056 
(17%) 
1334 
(18.5%) 
1557 
(19.5%) 
1867 
(20%) 
1320 
(20.5%) 
1183 
(20%) 
1202 
(20%) 
1080 
(20%) 
196 
(20%) 
Not indicated 62 (1%) 36 
(0.5%) 
40 
(0.5%) 
47 
(0.5%) 
32 
(0.5%) 
59 
(1%) 
60 
(1%) 
54 
(1%) 
10 
(1%) 
*Until 1
st
 March 
 
Considering IDCT at a national level, non-commercial research is more reduced. The percentage of 
non-commercial studies in Portuguese clinical research is less than 20% of the European average 
number of IDCTs. In Portugal, non-commercial sponsors accounts for 6% of the total number of 
CTAs to the National Authority of Medicines and Health Products (INFARMED). The highest 
number of IDCTs applications to INFARMED was 12, in 2009, of all 115 CTAs (16, 17). 
The number of Clinical Trial Applications per sponsor type, from 2006 to 2012 is presented in 
Table 8. Once again, these statistics represent the number of interventional studies that are 
submitted to INFARMED (16, 17). 
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Table 8 – Number of valid CTAs submitted to INFARMED, per sponsor type, per year (16, 17). 
 
Year 
2005 (2
nd
 
semester) 
2006 2007 2008 2009 2010 2011 2012 
2013 (1
st
 
trimester) 
Total number of CTAs 80 153 132 146 115 107 88 118 33 
Clinical 
Trials 
recorded 
by 
sponsor 
type (%) 
Commercial 76 (95%) 
145 
(95%) 
127 
(96%) 
139 
(95%) 
103 
(90%) 
101 
(94%) 
82 
(93%) 
112 
(95%) 
29 (88%) 
Non-
Commercial 
4 (5%) 8 (5%) 5 (4%) 7 (5%) 
12 
(10%) 
6 (6%) 6 (7%) 6 (5%) 4 (12%) 
 
In 2009, the European Medical Research Councils of the European Science Foundation analysed 
the problems and needs faced by independent investigators when conducting IDCTs. For that, a 
series of workshops covering different themes and attended by active and acknowledged experts 
in the field was carried. As a result a report was produced, Forward Look – IDCTs (10). This 
document identified specific issues that need to be addressed and recommend a range of possible 
solutions. Similarly, in 2011 the OECD Global Science Forum launched, at the initiative of the 
German and Spanish Delegations a “Working Group to Facilitate International Co-operation in 
Non-Commercial Clinical Trials”. This policy report also identified the main difficulties 
encountered by clinical researchers in setting up internationals clinical trials. Furthermore, they 
have recommended a series of policy recommendations aimed at overcoming the main difficulties 
faced in the process (10, 18). 
Based on these two reflection reports and the experience that I acquired contributing to the 
conduction of national and international IDCTs, a description of the main hurdles in conducting 
IDCTs are presented.   
Translational research is a powerful process that drives the clinical research engine. A strong 
clinical research infrastructure (comprising research centres and clinical trial units) is necessary to 
strengthen and accelerate the clinical research enterprise. These are centres of competence and 
excellence that are founded upon expertise and which provide access to patient-oriented 
research projects originating from the surrounding scientific community – academic, investigators 
or industry sponsors. The major need to perform high-quality investigator-driven clinical research 
is access to an infrastructure that functions as an aCRO offering centralized services and support, 
at affordable costs. This is particularly true when performing both multinational and multicentre 
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clinical research bringing together clinical research sites from different sites, with different 
requirements. Throughout the world, this type of infrastructure has been created in conjunction 
with AMCs. However, it may not be accessible to all sponsors of academic trials (4, 18). 
In addition, existing infrastructures may have limited capacity to deal with international clinical 
trials. In Europe there is a lack of such infrastructure for clinical and translational medicine. Like 
infrastructures, the number of available well-trained investigators, who are capable of working 
together and with other clinical trial professionals, is often lacking. In many cases young 
investigators are not being sufficiently well trained to cope with the actual multidisciplinary 
environment. Furthermore, investigators have little “protected time” from clinical duties to 
perform clinical research – there is simply too little time available to pursue research. There is a 
lack of job security and a clear, well-defined and predictable career path for clinical investigators. 
Participation in research usually does not bring a competitive salary, which contributes to 
uncertain future prospects. Academic freedom appears to be diminishing with researchers being 
constrained by regulations and guidelines, which leaves less opportunity for imaginative, 
innovative research (1, 18). 
It is very expensive to perform large-scale clinical trials. For this reason, large-scale clinical trials 
are mainly undertaken by the pharmaceutical industry for diseases that affect large numbers of 
people. Rare diseases groups or new indications for established groups are generally ignored. By 
the same token, funding for IDCTs was and frequently is lacking, even though such trials are 
capable of increasing basic understanding of diseases and improving healthcare. More public 
funding is required for academic clinical and translational research. The financial resources 
needed for national and especially for multinational European trials need to be secured. Funding 
should also be provided for both clinical investigators – to incentive the development of their 
careers – and specific infrastructures – to create optimal long-term clinical research. Such funding 
should be based on competitive peer-review and scientific and clinical excellence. This will assure 
that funding mechanisms for IDCTs will be coherent, instead of being heterogeneous and different 
between research’s fields (10, 18). 
The Clinical Trial Directive has brought about important improvements in the safety and ethical 
soundness of clinical trials in the EU and in the reliability of clinical trials data. However, the 
Clinical Trial Directive is arguably the most heavily criticised piece of EU-legislation in the area of 
clinical research. This criticism is voiced by all stakeholders – patients, industry and clinical 
investigators since (19): 
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• The number of applications for clinical trials fell by 25% from 2007 to 2011; 
• Increase of costs to conduct clinical trials – to handle clinical trials authorisation 
processes, the cost of staff needs have doubled. In the case clinical investigators, the 
increase in administrative requirements has led to 98% increase in administrative costs. In 
addition, since implementation of the Clinical Trial Directive, insurance fees have 
increased by 800% for industry sponsors. 
• The average delay for launching a clinical trial has increased by 90%.  
The actual Clinical Trial Directive has hampered the setting up and management of non-
commercial trials, particularly by the adoption of a “one-fits-all” national approach. In Europe, the 
same regulations that apply to higher-risk clinical trials of investigational medicinal products 
(IMPs) have been applied to all trials, regardless the risk involved and the objective of the trial. As 
a result, the requirements for low-risk trials, using already licensed drugs for similar indications, 
can be prohibitively onerous and time-consuming for academic institutions. In addition, the rules 
and regulations that govern clinical research are interpreted differently by the national and ethics 
committees’ authorities from different countries. Adding this to the lack of appropriate 
infrastructure, funding and administrative support previously mentioned, the opportunity to 
conduct clinical trials by investigators are limited. The three obstacles that constitute urgent 
challenges to be overcome by clinical research teams wishing to undertake international clinical 
trials are (10, 18): 
• Knowing about and understanding the existing laws and regulations, which can differ 
widely among countries; 
• Filling in the submission dossiers and defining the assessment procedures required by all 
the national competent authorities involved in international trials; 
• Answering to the different requirements of the numerous ethics committees involved in 
multi-centre studies. 
There is a need to make a distinction between studies whose risk is equivalent to standard (usual) 
care (including randomised trials that compare already marketed and labelled treatments) and 
those that are aimed at innovation (testing a new drug or medical device). The current 
classification of trials does not make this distinction and has similar requirements for all 
categories of interventional trials. An harmonised regulatory approach to clinical trials based on 
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risk needs to be developed and the requirements of different types of clinical trials need to be 
reviewed (10). 
With all the inconsistencies previously mentioned, launching and managing complex clinical trials, 
particularly at the international level, often remain a challenge for academic researchers. 
Approximately 24% of all clinical trials applied for in the EU are multinational studies. While these 
seem a relatively small proportion, this percentage of clinical trials involves approximately 67% of 
all subjects enrolled in a clinical trial. This means that, on average, a clinical trial with more than 
40 subjects is conducted in more than one Member State. Mono-national trials are limited to 
small studies with low recruitment targets (18, 19). 
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2. Generic Training 
 
The generic training provided by AIBILI allowed me to be familiarized with the activities of the 
institution and more specifically with the tasks of 4C. 
Since the area of expertise of AIBILI is ophthalmology, most of ongoing clinical studies are on 
specific eye diseases. Likewise, this was the clinical area that I was involved in my training and the 
basis of my generic experience. The knowledge acquired gave me has a better understanding of 
some pathological processes that occurs in the eye as well as some diagnostic and treatment 
procedures that are executed in ophthalmological clinical trials.   
A description of my training sessions, workshops and training course will be presented, according 
to the chronological order of occurrence.  
Training Session on Ophthalmologic Procedures 
The first training session that I had the opportunity to attend was on 14
th
 November 2012, under 
the subject of “Ophthalmologic procedures: methodology and support in diagnostic”. The session 
lasted three hours and was organised by the technical team of the clinical trial Research Centre 
(CEC) at AIBILI. This team responsible for the diagnostic procedures in the clinical studies is 
composed by 4 orthoptists: Pedro Melo, Ana Rita Santos, Mário Soares and Sílvia Simão.  
The program of this learning session was: 
• Definition of orthoptic; 
• Areas of expertise and competence; 
• Complementary exams in AIBILI; 
o Methodology and objectives; 
o Diagnostic support and treatment. 
 
This training was of major importance for me in order to understand the different ophthalmologic 
diagnostic exams performed in AIBILI. Specifically, I became more aware of the different 
equipment used, their principles of functioning, the techniques undertaken to perform the exams, 
their applications in the clinical practice and their outcomes. 
With this knowledge I could understand specific techniques and procedures mentioned in clinical 
studies protocols, as well as some requirements of inclusion and exclusion criteria.  
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Workshop: Investigator-Driven Clinical Trials – Relevance of New Structures in Portugal 
This workshop was held in the Institute of Biomedical Research in Light and Image (IBILI) of the 
Faculty of Medicine – University of Coimbra on 16
th
 November 2012, with two and half hours of 
duration. It was a workshop organised by 4C with open access to the general public, with the 
financial support of Bayer. The orators were José Cunha-Vaz (AIBILI), Rufino Silva (Coimbra 
Hospital and University Centre –CHUC/ CEC-AIBILI), Hugo Prazeres (Portuguese Institute for 
Oncology – IPO - Coimbra), Sandrina Nunes (4C-AIBILI), Cecília Martinho (EVICR.net), Pedro 
Caetano  (Universidade NOVA de Lisboa), Ana Pais (Universidade NOVA de Lisboa) and Ana Isabel 
Severiano (INFARMED). 
In this session various topics were approached, namely:  
• Different perspectives on the conduction of clinical trials in Portugal by investigators from 
AIBILI, CHUC and IPO; 
• The logistic and organisational support provided by 4C to investigators in clinical research; 
• European Thematic Network - EVICR.net; 
• Portuguese Clinical Research Infrastructure Network (PtCRIN); 
• Clinical Trial Portal – PNEC. 
With this workshop I became more aware of the difficulties faced by independent investigators 
that pretend to conduct clinical research in Portugal. Also, a new concept was introduced for me, 
the concept of aCRO. The existence of these structures is of major importance for investigators. 
They support all related trial-activities that need to be perform in order to implement a clinical 
trial.  
The European Clinical Research Infrastructures Network (ECRIN) has been established as a not-
for-profit infrastructure to support multinational clinical research projects. It started in 2004 with 
the first project on identifying the main bottlenecks to multinational cooperation in clinical 
research. This led to evidence of discrepancies in national organisation and practice of clinical 
research. As a result, ECRIN aimed to define a pan-European infrastructure for clinical research, 
based on the connection of national hubs providing services to multinational clinical studies. 
These national infrastructures provide services to investigators and sponsors in the conduct of 
multinational studies (20). 
In a national scenario PtCRIN (ECRIN’s member) aims to develop and to organise clinical research 
infrastructures, promoting its linkage and collaboration. This organisation concentrates efforts to 
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boost the productivity of all clinical research in Portugal, yielding a significant output of 
therapeutic innovation.  
This training session also proportionated me a more comprehensive knowledge of 4C’s scope of 
work and EVICR.net structure, objectives and ongoing studies. 
Workshop: New Technologies for Medical -Imaging 
This workshop was held in the IBILI’s auditorium of the Faculty of Medicine – University of 
Coimbra on 30
th
 November 2012, with two hours of duration. It was organised by CNTM and the 
orators were from CNTM – AIBILI: Rui Bernardes, Pedro Rodrigues, Pedro Guimarães, Conceição 
Lobo and João Figueira. Various topics were approached, namely: 
• Vascular network of the human macula from Optical Coherence Tomography (OCT); 
• 3D blood vessels segmentation form OCT; 
• Phenotype/genotype correlation in DR; 
• Adelphic eyes in macular holes. 
 
With this training I became more aware of the scope of work that is conducted in CNTM. I learned 
that fundus imaging is needed for early and accurate diagnosis, to guide initiation of therapy and 
to evaluate the response to therapy of retinal diseases. 
Training Session on Good Clinical Practices - ICH-GCP Guidelines 
This training session was held in AIBILI, on 17
th
 December 2012 and organised by UGQ Structural 
Unit. It took a total of four hours and was lectured by Cecília Martinho, AIBILI’s Chief Executive 
Officer (CEO). This was a very relevant training session because I could remind and consolidate 
some standards and concepts previously acquired during my academic education. Having 
knowledge on this international standard is of major importance because it states how clinical 
trials should be conducted; define roles and responsibilities of clinical trial sponsors, clinical 
research investigators and monitors. It assures that the human rights are protected during a trial 
and assures the efficacy and safety of new products. 
Training Course in Ophthalmology – Age-related Macular Degeneration and Angiogenesis  
This training course occurred in AIBILI, on 14
th
, 15
th
 and 16
th
 January, with a total of 15 hours of 
duration.  It was organised by the physicians and technicians of CEC. The trainers were Inês 
Marques MD, Maria Luz Cachulo MD, Sérgio Leal MD, Isabel Pires MD, Luísa Ribeiro MD MSc, João 
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Figueira MD MSc, Rufino Silva MD PhD, Pedro Melo BSc, Ana Rita Santos MSc, Sílvia Simão BSc 
and Mário Soares BSc. 
The main objectives were to present basic notions about the ocular’s anatomy and physiology, 
the pathologies of the eye and the complementary exams used to access eye fundus pathologies. 
Also, the course aimed to understand angiogenic mechanisms, to review the more important 
AMD clinical trials and to know the most recent treatment used in AMD clinical practice. The 
topics approached were: 
• Ocular anatomy and physiology. Clinical trials with anti-vascular endothelial growth 
factor; 
• Pathophysiology of AMD; 
• Complementary diagnostic procedures in AMD; 
• Therapeutics in AMD; 
• Main pathological processes in the eye; 
• Angiogenesis; 
• Therapeutics of exudative AMD. 
 
This training course was of major importance because I could acquire a more comprehensive 
knowledge about the clinical areas of AIBILI’s expertise. Also, I gained knowledge on the scientific 
background concerning AMD clinical trials that enables me to understand the current clinical 
practice for the treatment of this disease. This scientific information facilitated some of my 
activities during my curricular training, namely the elaboration of an Informed Consent Form (ICF) 
for a DR clinical study.  
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3. Specific Training 
 
According to the ICH-GCP a CRO is a person or an organisation contracted by the sponsor to 
perform one or more of a sponsor’s trial-related duties and functions (8). An aCRO also provides 
contract services to external commercial sponsors initiated studies in addition to support the 
design and conduct of investigator initiated studies. The task of development new products with 
smaller in-house staffs has led to pharmaceutical companies to increase their reliance with CROs. 
It is estimated that more than 60% of all clinical studies now involve significant outsourcing (21). 
A CRO can provide all services to the client in relation to the research project design, 
implementation and conduction. The main functions required to carry out a research project 
which are usually the departments in a CRO are (22): 
• Medical Function: personnel medically qualified who help the design of a clinical study, 
help to develop clinical trial protocols and provide medical related input throughout the 
study. This includes medical monitors, clinical research physicians (investigator) and 
medical advisors. 
• Regulatory Submission: this department assists in submitting various documents and 
obtaining approvals from regulatory authorities. It is composed by a regulatory affairs 
person. 
• Clinical Operations: this department is responsible for the conduction of the clinical 
research project (selection of clinical trial sites, conducts monitoring at sites, assists in 
study closeouts and helps in all study management). It consists of clinical research 
associates (CRAs), project managers, clinical trial assistants and project manager 
assistants. 
• Data Management: this department designs tools and databases to collect data (Case 
Report forms – CRF and Electronic Case Report Forms - eCRF). It helps to ensure that the 
data collected from clinical trials is clean and ready for analysis. It is composed by data 
managers. 
• Data Analysis and Statistics: department where study data are analysed according to the 
protocol. Biostatisticians help to generate statistical tables, figures and graphs and their 
interpretations are an input for the elaboration of the clinical study report. 
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• Medical Writing: Medical Writers help to write study-related documents (reports, study 
protocols, promotional material). 
As a project manager assistant, I had the opportunity to participate in different research activities, 
through different development stages of 11 clinical projects (Table 9 and Table 10). This 
experience gave me a broader vision of a clinical project’s life cycle.  
Table 9 – Participation in Clinical Research Projects during my curricular internship.  
 
Study Acronym Purpose Sponsor Design 
CEC-120 To assess Genotypes/Phenotypes correlations in 
type-2 DR 
IDCT Observational study 
Epidemiological To assess the prevalence of AMD in the 
Portuguese population with age greater than 55 
years-old and to characterise patients with this 
disease. 
IDCT Observational study with a 
single visit 
EUROCONDOR 
To assess whether neuroprotective drugs 
administered topically are able to prevent or 
arrest neurodegeneration as well as the 
development and progression of DR in its early 
stage 
 
IDCT Multinational, prospective, 
phase II-III, randomised 
controlled trial 
LHON Disease registry on LHON Industry Observational study 
Life Style and Food 
Habits 
Questionnaire 
To evaluate the frequency of nutritional and 
lifestyle risk factors whether separate and/ or 
joint have a major public health impact in terms 
of AMD 
IDCT Population of the 
Epidemiological study and are 
invited to respond a validated 
life style and food habits 
questionnaire 
Lucentis CNV To assess the efficacy and safety of Lucentis in 
patients with subfoveal and justafoveal 
choroidal neovascularization 
IDCT Multicentre, prospective, phase 
II, open-label 
Lucentis RD To assess the efficacy and safety of Lucentis in 
patients with high risk proliferative DR 
IDCT Multicentre, prospective, phase 
II, open-label 
Macugen To assess the efficacy and safety of Macugen in 
patients with high risk proliferative DR 
IDCT Multicentre, prospective, phase 
II, randomised controlled trial 
PROTEUS To assess the efficacy and safety of different 
treatment combination in subjects with high risk 
proliferative DR 
IDCT Multinational, prospective, 
phase II-III, randomised 
controlled trial 
RET-2012-02 To identify progression of retinal disease in eyes 
with non-proliferative DR 
IDCT Observational study 
STAR To assess the safety and efficacy and tolerability 
of eye drops as a complementary treatment for 
Diabetic Macular Edema. 
IDCT Multicentre, prospective, phase 
II, randomised controlled trial 
LHON – Leber’s Hereditary Optic Nerve Disease 
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Table 10  - Activities performed in different clinical research projects during my curricular training. 
 
Clinical Research 
Projects/ 
Activities developed 
Pre-Study Phase In-Study Activities 
Post-Study 
Activities 
Documents 
elaboration 
eCRF 
planning 
and 
validation 
Site 
Feasibility 
Construction 
of Study 
Files 
Study 
Management 
Data 
Management 
Data 
Entry 
Data 
Validation 
End of 
Study – 
related 
activities 
Archive and 
Destruction of 
Clinical Trial 
Documentation 
EUROCONDOR 
 
x x  x       
PROTEUS 
 
x x  x       
STAR 
 
x          
Epidemiological 
 
    x      
Life Style and Food 
Habits Questionnaire 
 
   x x x     
Macugen 
 
   x   x x x  
Lucentis DR 
 
        x  
Lucentis CNV 
 
         x 
LHON 
 
  x x       
RET-2012-02 
 
     x     
CEC-120       x    
24 
In order to describe my on-the-job training, I organised my activities according to its order of 
occurrence in a life cycle of a clinical project (pre-, in- and post-study activities -  
 
Figure 4). Also there were some activities that were independent of a clinical project’s stage of 
development, that are described as transversal activities ( 
 
Figure 4).   
 
 
 
Figure 4 – Activities developed during my curricular training, according to its stage in a clinical research project 
development. 
 
3.1. Pre-Study Activities of Clinical Trial 
 
Before initiating the clinical phase of a research project certain activities must be carried out. 
Specifically the study must be designed, clinical study-specific documents elaborated (protocol, 
ICF, source documents), Standard Operational Procedures must be developed. In addition, 
submission activities to the regulatory authorities are performed and contracts elaborated. 
 
Transversal Activities 
• Organisation and archive of mails 
• Research on specific topics 
• Revision of documents 
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3.1.1. Study Documents Elaboration 
Study Synopsis and Clinical Trial Protocol 
During my curricular training I had the opportunity to assist in the elaboration of a study synopsis 
and a clinical trial protocol. These were documents for the STAR and PROTEUS studies, two IDCTs 
on DR sponsored by AIBILI and EVICR.net and with the financial support of industry (Table 9).   
The study synopsis is a short summary of the clinical trial. It is used to design and plan the study. 
This document is usually used to access internally the study feasibility at the scientific, logistic and 
funding level. The study protocol is the basis of a clinical trial. The protocol addresses the quality, 
the ethical feasibility and the objectives regarding the efficacy of the IMP. The responsible 
authorities can only give approval when the operations and methodology are described exactly 
and every step repeatable for another research team (23). The authorities provide the sections 
and organisation of the protocol. The main sections are (23): 
• General information; 
• Background information; 
• Trial objectives and purpose; 
• Trial design; 
• Selection and withdrawal of the subjects; 
• Treatment of subjects; 
• Assessment of efficacy; 
• Assessment of safety; 
• Statistics; 
• Direct access to source data/ documents; 
• Quality control and quality assurance; 
• Ethics; 
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• Data handling and record keeping; 
• Financing and insurance; 
• Publication policy; 
• Supplements.  
The PROTEUS protocol was elaborated from an AIBILI standard template designed to comply with 
regulatory requirements, ICH-GCP and AIBILI’s policy. The project manager coordinate the 
different contributions in the protocol, namely from the coordinating investigator and the 
statistician. This document should meet the expectations and specifications defined by the 
coordinating investigator (24). 
As a project manager assistant, my role at the elaboration of the study protocol was the 
implementation of some changes previously agreed and a final revision. In the process I could 
note the importance of team work - different people, with different roles in the institution 
contributing to the same outcome, the elaboration of a clinical trial protocol. For the study 
synopsis, I collaborate at the writing of the eligibility criteria, which was the similar from another 
study, with the same scientific background. This experience enabled me to gain a more specific 
knowledge about these two documents, with special emphasis on its structures and different 
function. 
The Informed Consent Form 
The ICF is the most important document for the protection of human subjects in clinical trials. 
During the trial, it also protects the sponsor from legal consequences if the patient is harmed. On 
the other hand, the patient is instructed about all his rights and duties, as well as possible risks 
and foreseeable adverse events. It can be used as a contract between the sponsor and the 
participant (25). 
 The ICF consists of two documents: the information sheet and the consent form. They are usually 
considered as a pair of documents and not as separate ones. The ICF template contains a core 
information that applies to clinical trial specific information and information that may need to be 
updated according to the specific local requirements (24). 4C has two templates, one in English 
for multinational studies and a second in Portuguese for national studies. 
Concerning the ICF elaboration, I performed two activities: elaboration of an annotated ICF and 
an ICF for the PROTEUS clinical study.  
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For the elaboration of the annotated ICF, I introduced in the ICF template the specific 
requirements listed in ICH-GCP on the appropriate sections. This document serves as a “guide”, 
with specific explanations for its realisation, always complying with the current regulatory 
requisites. 
The PROTEUS study is a multinational study (Table 9) so the ICF has to be translated to the 
participating clinical sites, in different countries, according to their realities. For the elaboration of 
the ICF for this study I include the following information (25): 
• Explanation that the clinical trial is part of research; 
• Treatment during the trial; 
• Probability for randomized allocation to a study group; 
• Course of events and study design; 
• Rights and duties of participants; 
• Experimental aspects of the trial; 
• Foreseeable risks for participants as well as for embryo, foetus and nursed 
infants; 
• Expected benefits and the purpose of the trial; if there is no clinical objective 
expected the participant has to know as well; 
• Alternative treatments for the participant and their side effects; 
• Compensation and insurances for the participant if he/she is harmed; 
• Expense allowance and possible personal expenses for the participant; 
• Voluntary participation and possibilities for refusal at any time; 
• Open access for responsible monitors, auditors, Ethics Committees, health 
authorities to every medical document regarding the trial including original 
documents; 
• Data protection; 
• Preservation of anonymity; 
• Update changes of the trial for patients; 
• Contact person or institutions in case of harm; 
• Circumstances and reasons that can stop the participation or study; 
• Expected duration, 
• Approximate number of participants. 
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3.1.2. Electronic Case Report Form Design 
The CRF is a printed or electronic document that is created and used in clinical research to 
capture protocol required clinical data from each patient and to transfer it to data Management 
(26). It enables data to be typed directly into fields using a computer and transmitted 
electronically to Study Database. A well designed and properly structured eCRF is a prerequisite 
for simplified data collection and for minimisation of data entry errors. eCRF design technique in 
terms of eCRF layout, organising eCRF modules with comprehensive eCRF completion instructions 
are all necessities for its success (27, 28). 
Aligned and structured CRF fields provide a clear direction for data collection and for annotating 
eCRF and should always be organised in accordance with the protocol visits schedule. For 
example, demographic data and informed consent are always the first data collection modules in 
a eCRF followed up by the physical and laboratory assessments (28). 
The definition of the parameters to be collected such as the nature of the variable (scale, nominal 
or ordinal), the number of decimal units are critical issues for a well-designed eCRF, for example, 
pre-defined format for the laboratory units (Figure 5) (28). 
 
Figure 5 – Example of pre-defined formats for specific data units (28). eCRF – Electronic Case Report Form. 
 
The classical CRF and Electronic Data Capture (EDC) construction is an interactive process 
involving professional for different specialties (data manager, database specialist, an EDC 
programmer) - Figure 6 (29). 
I participate in the collection of all variables needed to include on the eCRF to a single document. 
As for variables, their specifications and units were also included. This activity was for the initial 
design of the PROTEUS study eCRF. Planning the design of eCRF by structuring study variables and 
specifications ensure that the information mentioned in the protocol is respected.  For this 
activity I have based some of my work in the variables of the EUROCONDOR study (an ongoing 
multinational study on DR - Table 9), since it has similar procedures. 
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Figure 6 – Interactive process of setting up a CRF and EDC (29). MS – Microsoft; DVP – Data Validation Plan; CRF – Case 
Report Form; e-CRF – Electronic Case Report Form. 
 
3.1.3. Data Management Plan and validation of an eCRF 
The scope of data management is: to deliver a computerised system to support the tracking; to 
carry out data capture and data cleaning of collected patient data and to support the clinical team 
in setting up various documents, specifying how the above activities should be defined and 
supported (30). So, data management plan describes the activities to be conducted in order to 
ensure that data is collected, validated, completed and consistent.  
The data validation plan is part of the data management plan. It describes either the automatic 
validation rules and electronic validation checks (automatic queries) being applied to the clinical 
data. Automatic data validation rules provide control for data accuracy. They are triggered during 
data entry, warning the user in real-time that invalid data is being saved. Electronic validation 
checks are used to fire a query message when discrepant data is entered. They help increasing the 
quality of the clinical trial data. Where data entered does not pass validation rules and/or the edit 
checks, and then a data query may be issued to the investigative site where the clinical trial is 
conducted to request clarification of the entry. Only the site staff with appropriate access may 
modify data entries (30). 
In the elaboration of the data validation plan, I had the opportunity to assist in the description of 
the validation rules concerning the data entry in the EUROCONDOR eCRF.  
As mentioned previously, I collaborated in the compilation of all the variables needed to be 
included in an eCRF of the PROTEUS study. It is a very preliminary activity for the eCRF 
development (Figure 6) (29). I had the opportunity to participate in another stage of eCRF 
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development.  During the construction of the EUROCONDOR eCRF I could also assist the study 
project manager in the validation tests of the various fields, from different clinical trial visits. This 
process was executed with two different access logins – investigator and administrator. Each 
login/password combination is related to an access role that grants permissions to read and/or 
write only on the designated forms and perform certain tasks. In this activity, I deliberately 
introduce abnormal values that are expected to bring a query. Then it is verified if queries are 
raised. If not, I registered the fields that are not executing validation checks and inform the 
EUROCONDOR’s project manager. It was an interactive process between me, the project manager 
and the entity outsourced responsible for the construction of the eCRF.  
 
3.1.4. Study Procedures Manuals – electronic Case Report Form and Laboratory 
Study procedures manual contains practical aspects of the study not included in the protocol. Two 
manuals that I had the opportunity to collaborate in their execution were the laboratory and the 
eCRF manuals, for the EUROCONDOR study. Being a multinational study, all these documents 
were posteriorly distributed to the participating sites, from different countries. 
The laboratory manual included regional information from the different sites, namely the 
reference ranges for the different laboratory testing. In this process, my functions were to 
compile and to integrate in a database the different reference values for biochemical, urine and 
haematological testing from the different clinical sites. It was an interactive process since the 
clinical sites commonly do not send the reference ranges for all the required testing. I had to 
communicate to the project manager the missing values, which in his turn had requested the 
missing values to the clinical sites. All this were performed in order to obtain complete 
information for the elaboration of the laboratory manual, within the established deadlines. Once 
the information was completed, I could update the reference ranges in the right section of the 
laboratory manual. 
The eCRF manual provides guidance to use the electronic data capture platform. Specifically in the 
EUROCONDOR study manual, I wrote the orientations for the completion of inclusion (baseline) 
and follow-up visits and the adverse event forms. After the elaboration of the eCRF manual a 
PowerPoint presentation was done in order to provide training to the CRAs of the different 
countries. I could assist in the elaboration of this presentation. Furthermore, I had the 
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opportunity to attend the training session provided by the project manager to all CRAs involved. It 
was teleconference training and occurred at 5
th
 December 2012.  
 
3.1.5. Clinical Trial Feasibility 
Delays in study start-up and patient enrollment are major problems for cost overruns in clinical 
trials. A well-designed and executed feasibility study is crucial to overpass this problem. Using a 
feasibility questionnaire it is possible to assess whether a given study can be conducted in a given 
clinical site. Several aspects can be studied: 
• Regulatory challenges; 
• Available patient population; 
• Required expertise; 
• Available equipment. 
 
During my curricular training I had the opportunity to participate in the process of selecting 
clinical sites for an observational study. It was a disease registry in patients with Leber’s 
Hereditary Optic Neuropathy (LHON), a rare disease that attempt to collect data of the patients 
that are followed at each clinical site (Table 9). It is a collaboration between Industry and 
EVICR.net. 
Using a survey service-platform (Lime Survey), I was responsible to send the feasibility 
questionnaire to all the EVICR.net members sites (76 clinical sites from 16 European countries). 
For that, I constructed the questionnaire in Lime Survey after studying this tool. On the past 
feasibility assessments, the clinical sites received an email with the questionnaire in attachment. 
The study staff had to print it, respond to it on paper, scan and then send it by an email. This was 
the first activity using this online survey service. The activities involved on the study of Lime 
Survey will be described later. 
After sending the feasibility questionnaire a reminder for the clinical sites was sent. The dates for 
sending the questionnaire and the reminder and its closure were previously agreed. During this 
process I followed-up the results to the questionnaire and compiled them in a single database for 
further analysis. In the agreed deadline there were few responses to the feasibility. Another 
measure had to be taken, specifically contacting the non-responders sites telephonically and 
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appealing for a response. I could assist the EVICR.net contact person in these calls. During this 
activity I contacted 4 clinical sites from Greece, Italy and Spain. 
Other activity associated with this service was the feasibility reports to the sponsor. I also assisted 
in its elaboration, namely by providing information on the response status of all the clinical sites 
and in the text organization. 
Lime Survey – an online survey service 
As mentioned before, I was responsible for studying Lime Survey tool for further implementation 
in 4C and UGQ’s activities. Besides the different contexts (clinical studies and quality management 
system) the tool can be equally used for sending and managing questionnaires. Initially another 
online survey service was studied – Monkey Survey. Different questionnaires were done under 
these two online programs (an already existing feasibility questionnaire and a questionnaire to 
evaluate client satisfaction). Then, I elaborate a comparative document concerning their 
characteristics on the survey construction (Apendix I), sending to participants and analysis of 
results. After discussing this conclusion with AIBILI’s CEO, it was agreed that Lime Survey was a 
better practical choice. 
Once chosen Lime Survey as the tool to send and manage questionnaires I elaborated a user 
manual for its main features (Appendix II). Also, it was agreed that I would provide a practical 
training session. It is schedule for 11
th
 June and the attendees are UGQ and 4C’s personnel. The 
training session will consist on the elaboration, sending an analysis of a feasibility questionnaire. 
At the end, the attendees will have to construct another questionnaire that will be revised and 
evaluated by me.  
 
3.1.6. Management of Study Files 
An important task assigned to me during my curricular training was the elaboration and 
management of study files. The organisation of Clinical Trial Documentation in 4C follows the ICH-
GCP and the requirements specified in the AIBILI’s Quality Manual (31).  
The trial master file is the record for documentation and archiving of all accumulated study 
documents, particularly with regard to essential documents for conducting clinical trials. At the 
beginning of the trial, the sponsor and monitor are responsible for the documents stored in the 
trial master file. It is very important to keep study documentation organized in order to assure the 
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validity, quality and reliability of the obtained data. Thus, the organisation and handling in the 
trial master file assumes an essential role, particularly when the data may be inspected by the 
health authority or other competent authorities (32). 
Since AIBILI is the sponsor of many IDCTs supported by 4C, trial master file are established, 
organized and storage at 4C facilities. The structure of investigator and trial master files are 
established according to the AIBILI’s quality policy (33, 34). Additionally to the trial master file, for 
the EUROCONDOR study were also established trial master files site specific, containing specific 
information of each clinical site, in different countries.  
The following list is according to ICH-GCP and represents the essential documents needed before 
the clinical phase of the trial starts (32): 
• Investigator’s brochure/Summary of Product Characteristics or other specific and current 
information about the IMP; 
• Signed clinical trial protocol and amendments, as necessary, and the blank CRF design; 
• ICF; 
• Financing statements; 
• Insurance statements; 
• Signed contracts between the trial parties; 
• Opinion and composition of the Independent Review Board; 
• Any written information provided to study participants; 
• Authorisation/approval/notification of the protocol by the health authority in compliance 
with the applicable regulatory requirements; 
• Documents regarding the qualifications of the sponsor-investigator/subinvestigator(s) and 
other involved trial staff; 
• Normal value(s) and range(s) for medical/laboratory/technical procedures and tests as 
well as the proof of competence of the procedure and/or test; 
• Sample labeling of the IMP container(s); 
• Instructions concerning the IMP an trial-related materials, in particular: 
o Handling (storage, packing, dispensing); 
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o Distribution (distribution dates and method, batch numbers, tracking, condition 
review and accountability); 
• Decoding procedures for blinded trials; 
• The Master Randomization List; 
• The Pre-Trial Monitoring Report/ Trial Initiation Monitoring Report, especially in case of 
multicenter trials.  
I managed the trial master files for the EUROCONDOR, PROTEUS, LHON, MACUGEN, and Life style 
and food habits questionnaire. 
An important part of the clinical trial files is its correct identification and logical organization in a 
harmonised way. This is very important in order to easily identify the clinical study and its 
content, tracking the information and allow a person exterior to the study to locate required 
documentation without problems.  
The AIBILI’s quality Manual specifies the requirements needed for the file’s spine. The information 
that must be present is (31): 
• Name “AIBILI”; 
• Name “4C”; 
• Service Identification: “Protocol Number/ Code/ Acronym”; 
• Service Intern Number; 
• Dossier Identification (Master File, Investigator File); 
• Sequential Number of Dossiers (Volume). 
 
I was responsible to set up and update the spines of the dossiers as the clinical study occurred. I 
established and updated spines for all clinical studies carried out by 4C. 
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3.2. In-Study Activities of Clinical Trial 
 
The conduction of the clinical phase of a research project is characterised by the execution of 
activities related to data management and coordination. Also, monitoring activities are performed 
in order to assure the quality of data generated through the clinical phase. Data management, 
data validation and pharmacovigilance activities are also other activities in this clinical phase. 
Periodical reports to the sponsor and Regulatory Authorities are also performed. 
 
3.2.1. Study Management and Follow-Up Activities 
The most frequent and time-consuming activity that I undertook was study management and 
coordination. The related activities on this topic were performed for two studies “Epidemiological 
Study on the prevalence of Age-Related Macular Degeneration in Portugal” and “Life style and 
Food Habits in population aged >55” (Table 9). These are studies are intimately related. 
Epidemiological Study on the prevalence of Age-Related Macular Degeneration in Portugal 
This study has the purpose to assess the prevalence of AMD in the Portuguese population with 
age greater than 55 years-old and to characterize the patients with this disease. The study has a 
single visit, performed at the primary health centres (Mira and Lousã). It consists in an interview 
to the participant and the acquisition of Color Fundus Photographs (CFPs) that will be graded by 
CORC. Subjects with probable diagnostic of AMD are referred to a Retina Visit in a Reference 
Hospital. If the patient is not followed-up in a reference hospital, they are scheduled for AIBILI 
medical observation. 
Nowadays this study is close to the end of the clinical phase at Lousã. In order to reach the 
estimated number of patients needed for statistical analysis, the project manager had to adopt 
some tasks related to the study dissemination, which were assigned to me. It was decided that 
the coordinating centre has to contact the local radios in order to obtain a budget for the study 
advertising. Also, the parish centres need to be contact in order to obtain permission for the 
distribution of some study leaflets.  
I contacted the radios S.Miguel 93.5 and S.André 100.5 requesting a budget for an advertising of 
58 words. This promotion was previously elaborated by the project and study managers. After the 
telephonic contacts, I elaborated official letters to send the leaflets.   
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Furthermore, systematically I checked the correctness of the ICF data, namely if they were 
correctly signed and dated. If not, the principal investigator has to correct it.  
Periodical Reports 
With defined time spans, follow-up reports must be sending to the research team. In this context, 
a preliminary report was done with data from patients already included. Important information to 
be included were: number of patients included, patients already graded, % of retinal changes, % 
of Age-Related Maculopathy patients, % of wet AMD patients, % of Geographic atrophy patients, 
% DR patients and % of other changes. For the elaboration of this report I used an existent 
template and completed the required sections according to the protocol. The information about 
the study patients had to be adapted. I elaborated a consort chart to describe the study 
population at the time of the report. This scheme showed the number of all patients registered in 
the primary healthcare unit in Lousã. From this total, the patients contacted are organized 
according to whether or not the study visit was scheduled. Of the patients that do not have a 
scheduled visit, the reasons are presented and specified in numbers. From the scheduled 
participants, the number of attendees was also pointed. The preliminary report also included 
statistic data for demographic and potential risk factors for AMD. However I do not contribute for 
this part. 
Apart for this preliminary report, the activity of study staff has to be closely monitored, namely 
the number of patients included and the exams graded by CORC. I assist in the elaboration of the 
periodical follow-up newsletters to the coordinating investigator, showing the inclusion status of 
patients.  
An important activity that I contributed was the identification of patients included in the 
epidemiological study that are currently followed-up in CHUC. It is important to have this 
information in order to assess their medical history. For this, I crossed information from two 
databases and filled a medical file requisition form for all these patients. Once the medical files 
arrived at AIBILI, the study investigator could collect information to include in the study. 
Life style and Food Habits in population aged >55 
The study “Life style and Food Habits in population aged >55” is an extension of the 
“Epidemiological Study on the prevalence of Age-Related Macular Degeneration in Portugal”. The 
study consists in a single visit where subjects that participated in the Epidemiological study are 
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invited to answer a validated life style and food habits questionnaire, after signing a written ICF. 
At this study I assumed many activities.  
Currently the study is taking place at the healthcare Unit of Lousã. The interviewers are voluntary 
students of “Escola Superior de Tecnologia da Saúde de Coimbra” attending the dietetics and 
nutrition course. During the study, I was responsible to invite telephonically the participants to 
answer the questionnaire in a specific weekly date, previously accorded with the dietitian 
students. Subjects that could not attend the visit, I re-scheduled them. The data collected during 
the visit were registered directly in the questionnaire. After the interviews, the project manager 
meets the students and received the completed questionnaires. Then I was responsible for the 
completeness and accuracy of the answers of the questionnaire. I checked questions not 
answered as well as crossed information in the questionnaires and ICF. In order to follow ICH-
GCP, either ICF or questionnaires that have crossed information must be correctly signed and 
dated. When this requisite was not meet, I pointed out the specific document for further 
correction by the interviewers.  
Alongside with this process, I elaborated and updated a database for the follow-up of 
participants. I registered the completed questionnaires by date of visit and participant 
identification data (number of participant and date of birth). Also the AMD diagnostic information 
from the epidemiologic study was assessed. These enable me to monitor the AMD disease status 
of completed questionnaires. Due to the need to have an equilibrated proportion of healthy and 
AMD diagnosed participants, I could control the scheduling of patients under these requirements. 
In addition, the patients referred to AIBILI for ophthalmological observation were as well eligible 
to answer the food and lifestyle habits questionnaire. At this stage, I received training and acted 
as an interviewer. I was responsible to follow the visit dates of epidemiological participants and 
administered them the questionnaire. Each subject must have given written informed consent 
before the participation in the study. At this process I explained the objective of the study and the 
need to use the data obtained, always ensuring the participant confidentiality. 
The study logistics were also under my responsibility. I filed the questionnaires and the ICFs in the 
respective master files, according to an increasing date of realization. I also managed the prints of 
these documents, in order to assure that the primary healthcare unit of Lousã has permanently an 
available stock. At the same time, I scanned the completed questionnaires for the dietitian 
students registered the data collected in an appropriate database. 
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3.2.2. Data Management 
The workload in assembling clinical trial data for analysis is dictated by the quantity and the 
quality of data. Two essential features of data management are a validated computer system and 
a trained specialist staff. 
The ECR-RET-2010-02 study is a multinational, observational study with the purpose of identifying 
eyes with DR that show worsening and retinal disease progression, in diabetic type 2 patients 
(Table 9). For that, non-invasive procedures have been taken through 4 visits. This study does not 
have an eCRF. Instead, designated investigator staff entered the information required by the 
protocol on to paper CRFs. Data from the paper CRFs will be entered by each site in the Study 
Data Worksheet, an excel data sheet, using single data entry. This worksheet was previously 
prepared by 4C and sent to the participating clinical sites, from different countries. 
Each clinical site has to send to the coordinating centre monthly a copy of the Study Data 
Worksheet. Also, after a study discharge visit, a copy of the completed CRF has to be sent (by 
email or fax).  
In 4C, under this study my activities were to support the process of completeness and accuracy of 
the CRF and the Study Data Worksheet entries. The coordinating centre has access to all relevant 
source documents. Thus, with this information I could confirm the consistency of source 
documents data with paper CRF entries and the adherence to inclusion/exclusion criteria. When 
abnormal values were encountered, study personnel were instructed to make the required 
corrections or additions. Where Study Data Worksheet data were absent, I registered the missing 
information on a site - personalised document. Afterwards I transmit to the main project manager 
this information: missing or abnormal values. In her turn, the project manager contacted the 
clinical sites to ask for further clarification on these values. 
A follow-up of the monitoring process outcome were also performed. I updated the information 
contained in appropriate databases concerning missing data, study subjects visits dates and dates 
of the received CRF. The number of subjects under study, drop-outs, and screening failures was 
continuously followed-up.   
At this study some incongruities has been found. Some clinical sites send the CRFs (on paper or 
email) and do not fill the Study Data Worksheet. In this cases I entry the data on the specific 
worksheet and scanned the CRFs. It must be pointed out that this study has no financial support 
and was the first IDCT sponsored by the EVICR.net. 
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3.2.3. Data Entry 
Remote data entry is the process by which data are entered from the paper CRF into an electronic 
database (24). This is applicable only in the case of paper CRF retrieved from the sites to the 
sponsor. In this case, the database will need to be designed. The data structure should be laid out 
to be as consistent as possible with the other studies. 
The Macugen study is a national prospective, randomized, open-label, phase II study (Table 9). In 
this study paper CRFs were used. As defined in the protocol, data from the CRFs were entered 
into the study database by 4C staff using single data entry. I follow this study at the end of its 
clinical phase. In this context, it was assigned to me the data entry activity. In the course of 
collecting and entering data in the database, errors were found. The process of correcting errors 
is called data cleaning. At this process I point out in the paper CRFs the discrepancies found and 
communicated them to the project manager. Also, when I was unable to read the entry 
information, the project manager was notified so that the entry could be clarified with the person 
who completed the CRF. Further clarification was sought.  
With the queries clarified, the paper CRF was corrected and I introduce the new information in 
the database.  I could also assist in the design of the database. 
According to ICH-GCP, the sponsor should retain all of the sponsor-specific essential documents 
pertaining to the trial (8). Since the study had a single clinical site – CEC, AIBILI, I made copies of 
all CRFs. In this way, the sponsor could have records for this documentation for posterior archive.  
The CEC/120 is an observational study to assess the genotypes/phenotypes correlations in type 2 
DR (Table 9). For this study, 412 diabetic patients enrolled in a two-year prospective study (CPM 
study) were invited for genotype analysis. Specifically in this study I collected from the 412 
patient’s CRFs the values from BCVA at baseline (visit 1) and OCT exams from the 3 visits. For this 
task, due to the elevated number of CRFs, I collected the data in CEC, and introduce it in a proper 
database.  
 
3.2.4. Data Validation 
Data validation is the process of testing the validity of data in accordance with the protocol 
specifications. These databases are constructed according to the logic condition mentioned in the 
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data validation plan (previously mentioned in 3.1.3. Data Management Plan and validation of an 
eCRF). 
Since the Macugen study does not have an eCRF, and the data entry process was remote, the 
validation process was also manually. With the help of the study manager, a second pass and 
verification step of all data entered was performed. The discrepancies between the first and 
second pass was resolved in a way that the data entered was a true reflection of the CRF content. 
 
3.2.5. End of Clinical Study-Related Activities 
As previously mentioned, I could follow the Macugen study when it was reaching the end of its 
clinical phase. At this stage, I could assist the study CRA in several activities. 
First, INFARMED and Comissão de Ética par Investigação Clínica must be notified that the clinical 
trial ends its clinical phase. For that I fill the mail envelopes to be sent to the national ethic and 
regulatory authorities.  
According to ICH-GCP, all clinical trial materials and IMP that have been used, partially used or 
unused but are no longer required for the study must be reconciled and disposed of appropriately 
(8). All IMP supplies need to be returned to the Sponsor or destroyed at the clinical site. This must 
be done with approval from the Sponsor and must be fully documented (8). 
When IMP are returned to the Pharmacy department, IMP containers and their remaining 
contents for each clinical trial must be accounted for and documented in the Pharmacy file 
specific for that study. In the Macugen study I filled an “Investigational Product Return/ 
Destruction Form”. In this document, the treatment units of the IMP for destruction/return were 
registered. Specifically, for each used or unused IMP, were specified the number of units, its batch 
number and the code breaking envelopes number. As agreed with the Sponsor (AIBILI) the clinical 
trial IMP was destructed on site (CEC). The unused IMP units (intravitreal injections of pegaptanib 
- Macugen) were disposed in a specific needles container.  The remaining IMP package was 
disposed at the category-IV garbage container. 
I performed a similar task for the study Lucentis RD. It is a national prospective, randomized, 
multicenter open-label phase I study and is still ongoing (Table 9). 4C, as the coordinating centre 
for the study, has make accountability checks and record the number of units that each clinical 
site receives. At this point, the CRA assigned me the filling of the “Investigational Product Return/ 
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Destruction Form”. This way is it possible to maintain an audit trail of study IMP dispensed for 
further analysis of unused and used medication units. 
 
3.3. Post-Study Activities of Clinical Trial 
 
Post-study activities of clinical trial concern the analysis of data with regard of the Final Study 
Report elaboration and posteriorly the scientific publication. Any required regulatory reports are 
addressed. Clinical trial-related documentation is archived and when applicable some documents 
are destructed. 
 
3.3.1. Archiving and Retention of Clinical Trial Documentation 
Archiving is the long term storage of all essential documents which individually and collectively 
permit the evaluation of the conduct of a clinical trial and the quality of the data produced (9). 
According to Article 17 of Directive 2005/28/EC, essential documents should be retained securely 
prior to archive and then retained for a specific period of time (35). Archiving of clinical trial data 
must be carried out in compliance with the Clinical Trial Directive, volume 10 of Eudralex – The 
Rules Governing Medicinal Products in the EU and ICH-GCP (35). Whilst the ICH-GCP do not 
explicitly define “archive” in the Glossary, they state that “all clinical trial information should be 
recorded, handled and stored in a way that allows its accurate reporting, interpretation and 
verification” (8). 
Lucentis CNV was a national, prospective, multicenter, open-label study (Table 9) approved by the 
National Competent Authorities. Besides having a clinical trial authorisation the study was 
cancelled since the National Ethics Committee required conditions that were not feasible for an 
IDCT.  
According to the ICH-GCP, if the Sponsor discontinues the clinical development of an 
investigational product, the Sponsor should maintain all Sponsor-specific essential documents for 
at least two years after the formal discontinuation or in conformance with the applicable 
regulatory requirement(s) (8). At this point my function was to prepare the archiving process of 
the study specific documents, following the instructions of the AIBILI’s Internal Quality Manual. 
For that, I filled the “Submission of Material to the Archive” and the “Clinical Trial Archive Record” 
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forms. In these documents, the number of all sheets in the submitting files was counted. They 
were specified by chapters.  The compiled study documentation was saved in appropriate 
dossiers, identified under specific instructions. These are counted and also registered in the forms 
previously mentioned. 
In addition to the archive of the Lucentis CNV study, I also prepare the submission of another 
service carried by 4C. The service was named “ATRAL” and consisted in monitoring services of a 
phase I study carried out by CHAD. The CRA of this study was from 4C.  
For this process the same forms were filled and the documentation were also organised as 
previously mentioned.  
 
3.3.2. Destruction of Clinical Trial Documentation 
I carried out the destruction of trial documentation of the Investigator Files for the Study Lucentis 
CNV that was cancelled. Since the study did not start, the investigator files were not distributed to 
the clinical sites. Thus, they do not possess any essential and site specific trial documentation 
(35). The common documents where destructed and the files re-used.  
 
3.4. Transversal Activities of Clinical Trial 
 
Transversal activities of clinical trial were independent of the clinical project’s stage of 
development, and occurred whenever the work undertaken in 4C demanded.  
 
3.4.1. Online Research Activities on Specific Topics 
During my curricular training I performed many online research activities on many different 
topics. It has showed to be a great opportunity to strength the research tools gathered in the 
Biomedical Sciences Degree, from the problem based learning activities. Always looking for online 
reliable sources and criticising the data which the information was produced, I research the: 
• Data validation plans; 
• Elaboration of surveys in the programs Lime Survey and Monkey Survey; 
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• Statistical measures for inter-rater agreement; 
• Parameters for clinical software validation; 
• Summary of all clinical trials registered in the clinicaltrial.gov platform involving some 
medical products; 
• Guidelines for the conduction of registries studies; 
• Differences between personal data and study data; 
• Description of the genes involved in the clinical study CPM/CEC/120. 
I gathered as much relevant information as I could. Next the information were compiled and 
studied. As a final result I presented the document with the information summarized and 
explained the main ideas for the senior project manager who requested the activity.   
 
3.4.2. Revision of Documents 
Another activity that occurred with undefined time spans was the revision of different 
documents. In these activities I look for possible spelling errors and any discrepancies. The 
following documentation was subjected to revision by me: 
• CHARTRES study synopsis; 
• Quality General Procedure number 16, English and Portuguese versions. It is a procedure 
included in the Quality System Manual concerning the  implementation, coordination and 
monitoring of clinical studies undertaken by 4C; 
• “Logistic and organizational support needed – aCRO’s” presentation, included in the 
workshop “IDCTs – Relevance of New Structures in Portugal”; 
• “Good Clinical Practices” presentation, for the workshop about ICH-GCP; 
• “EUROCONDOR: eCRF Training” presentation, for the EUROCONDOR’S CRAs training 
session; 
• Initiation visit presentation for the C-TRACER clinical study. 
 
Most of these documentations were for oral presentations. Concerning the C-TRACER initiation 
visit, I also had the opportunity to attend it. 
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3.4.3. Organisation and Archive of emails 
Organizing and archive emails correctly are a major requirement for the management and 
coordination of a clinical project. The trial master file and the studies files should be kept 
organized and actualized.  Also, these files are eligible for inspection by the regulatory authorities 
at any time during and after the study is completed and submitted for product approval. It is 
therefore, paramount that these documents are filed in a way to make them immediately 
accessible for use by the study team and for regulatory inspection. 
A project manager should ensure that this documentation is ready for auditing at all times and 
that the study team can locate and use the information in a timely manner. This is even more 
important in the context of multinational clinical trials, where the amount of correspondence is 
bigger and its organization is more difficult. 
In this context, I assisted the project manager to achieve and organise correspondence in the 
clinical studies under their responsibilities. The studies were: EUROCONDOR, Lucentis RD, 
Lucentis CNV, Macugen and LHON. In this process I organised the emails from the most recent to 
the oldest. From this activity I learned that it is very important to keep every decisions and 
exchange of ideas written. Having a response written in an email is a proof of its occurrence and is 
crucial for the clinical project conduction. 
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4. Discussion 
 
Work in a clinical research coordinating centre gave me the chance to have a broader vision of a 
clinical research project’s lifecycle. According to models of industry- investigator partnerships 
described in Table 6, the the model “one company – one investigator” is the reality that I 
contacted during my training. Companies support financially investigators who could be 
supported by coordinating centres in all activities needed to design and conduct clinical research.  
Being involved in 4C’s activities has enabled me to contact with an unfamiliar reality in the clinical 
research environment – the one that is initiated by independent investigators.  
Personal experience, skills and competences gathered 
My curricular internship included generic and specific training components. The generic training 
consisted in two distinct training sessions on ophthalmologic procedures and ICH-GCPs, two 
workshops on the relevance of new structures that support IDCTs and new technologies for 
medical imaging and a training course on AMD and angiogenesis. The activities carried out in my 
specific training followed the whole clinical research project’s lifecycle. I had the opportunity to 
assist in pre-, in- and post-study activities. In addition I perform several tasks that I consider in this 
report as transversal activities since it were independent of the stage of development of a clinical 
research project. 
The generic training of my curricular internship has enabled me to be familiarized with the 
activities of AIBILI and more specifically with the tasks carried out by 4C. At the training course it 
was possible to me to integrate the steps occurred in an inflammatory process, since it was 
already addressed in the Degree of Biomedical Sciences. As an outcome of this training I acquired 
knowledge on the main diagnostic ophthalmologic exams and the diseases – AMD and DR, their 
pathological processes and current therapeutics. 
I really appreciated the fact that these training meetings occurred in an initial phase of my 
internship since it had allowed to integrate this knowledge on the current activities held in 4C. 
With these information contextualized and clarified, interpreting clinical trial protocols, writing an 
ICF or even managing clinical data become easier.  
With the specific training had the opportunity to develop personal skills and acquire competences 
as a clinical research professional needed to integrate the current labor market. 
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Working in a RTO was a very enriching experience. I could contact with different departments 
inside the same institution and understand their different roles in the development of a clinical 
research project. At AIBILI, I gathered a whole new vision of team work for clinical research 
projects design and conduction. I could assist the “birth” of clinical projects at 4C, the initial share 
of knowledge and seek for funding. At CEC, the clinical studies initiated by AIBILI are carried out. 
The ophthalmologic exams are graded by CORC during the conduct of the study. CHAD in its turn 
is responsible for pharmacovigilance tasks. The reality of AIBILI is a true example of team work 
that needs a coordinating centre to ensure the quality in the clinical research project’s 
conduction. 
The multidisciplinary environment of a clinical research coordinating centre showed to be a major 
advantage in my training. I accomplish to acquire professional competencies for the development 
of clinical research projects activities through different project’s lifecycle stages. I could 
participate in several activities: study documents elaboration, planning and validation of an eCRF, 
data entry and data validation, feasibility assessment, study and data management and archive 
and management of clinical trial documentation. In addition I could also assist the study monitor 
in end of clinical trial-related activities.  
As the professional competencies acquired, I highlight: 
• Comprehensive knowledge of the activities developed by a clinical research coordinating 
centre, acting as an aCRO; 
• Knowledge of the role of a project manager assistant in all research project’s lifecycle 
activities; 
• Knowledge of the particularities associated with IDCTs; 
• Development of follow-up activities associated with observational IDCTs management; 
• Knowledge on the elaboration of study-related documents, namely the study synopsis, 
study protocol, ICF, Data Validation Plan, Laboratory and eCRF manuals; 
• Knowledge on the planning and validation of an eCRF; 
• Autonomy in the elaboration and management of study-related files; 
• Development of data entry, management and validation activities; 
• Knowledge on site feasibility activities; 
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• Knowledge on archiving and destruction of clinical trial documentation; 
• Development of solving-problems strategies; 
• Development of my English skills, both written and spoken. 
I could also develop some personal skills. I point out the following personal skills improved: 
• Time management by establishment of priorities; 
• Adaptation to a new professional context; 
• Fulfilment of tasks in the deadlines established; 
• Team spirit and sense of responsibility; 
• Analyse information critically; 
• When communicating ideas, adaptation of speech and its content according to the 
listener. 
I would also like to point out another aspect that was mandatory for the conduction of my 
activities in 4C. The fact that 4C’s team has a good work environment facilitated my integration 
into the team. The personnel that work in 4C has a very solid team spirit, where opinions are 
taken into account and mutual help are frequently asked. Besides my lack of professional 
experience, I always feel like belonging to an already established team. This was crucial to the 
success of my curricular training. 
Difficulties faced during the performance of some activities and strategies implemented 
Life Style and Food Habits in Population Aged >55 
The first challenging activities that I would like to address is related to the study “Life Style and 
Food Habits in population aged >55”. It was the study where I spent more time working, 
moreover is where I can identify most the challenging activities and to establish improvement 
strategies. For start, the process where I contact telephonically the subjects of the 
Epidemiological study and invite them to participate in the food habits and life style questionnaire 
was not easy. I must explain that they are being invited to respond a food habits questionnaire 
because they already had participated in the Epidemiological study. It was an independent study, 
but only these subjects were being included. As a result of the telephone contacts, the 
participants who arrived at primary health care unit of Lousã thought they were going to do new 
eye’s exams, like the previously CFP in the Epidemiological study. The messages do not translate 
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correctly and they do not understand the correct objective of their visit to the health care centre, 
being unsatisfied with the situation and refusing answering the questionnaire. At this point I had 
to adopt a new strategy to invite the subjects to participate in the questionnaire. I wrote a 
“guideline” with the topics that were very important to mention in the conversation.  Just before 
ending the phone call I remind the date and hour of the appointment with the dietitians and that 
during it they will not perform any exam, just answer food-related questions. After changing my 
strategy at the phone conversations, the study participants arrive at the health care centre 
understanding their role at this visit. It is necessary to take special attention to the fact that these 
participants are 55 or more years of age. I should adapt the speech and choose carefully simple 
words to transmit ideas.  
In addition, it has been very important to understand if the persons that cannot schedule a 
specific day for the realisation of the questionnaire actually are interested in participating in 
another date or are really not interested. It happened that the subjects that asked to be re-
schedule when contacted for another date showed to be not interested. Again the need to have a 
concise, objective and simple speech became crucial in order to optimise this process and save 
time. I started to asks specifically if they would like to participating in another visit date instead of 
the “I call you later for a re-scheduled date”. Maintaining a complete and accurate database of 
the telephone contacts status showed to be crucial for saving time in the process of scheduling 
patients.  
Other aspect related to the life style and food habit questionnaire that had proven to be 
challenging was the obtaining the signing ICF. When the participants of the Epidemiological study 
were referred to AIBILI for ophthalmological observation, I administered them the life style and 
food habits questionnaire. For this, first it must be obtained a written informed consent. In this 
process, the participants that could read the information provided, preferred that I explain to 
them its content. Again, with a careful speech with simple words I had been explaining the 
objective of the questionnaire, how it is constituted and ask for they authorisation by signing the 
ICF. At this point having the capacity to summarise the information was very important. I had to 
be sure that the participants understand what I was asking. This was a process that became easier 
over time and more ICF were explained. 
Complying with ICH-GCP requirements shows to be a process present at each stage of the 
conduction of the life style and food habit questionnaire. When checking the completeness and 
accuracy of answers it was very important to check any crossed information that was not signed 
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and dated. Every time that happened I have been pointing it out in the questionnaires/ICFs for the 
dieticians posteriorly sign and date. These are aspects that are checked in any internal or external 
audit, and it must be rigorously verified. Over time become easier to identify inconsistencies in 
the questionnaires and ask for further revision/correction. It had been happening that the ICFs 
were incorrectly filled and remains necessary to be as rigorous as possible. It would be of greater 
value if the dieticians could have had a training session addressing the application of ICH-GCP into 
the administration of the life style and food habits questionnaire and the ICF at their initial 
training as interviewers. 
By assisting the study manager coordinating the activity of the dieticians I could note how 
important is to motivate and have a motivated team. A project and study managers have an 
essential role in motivating and stimulating the clinical team in order to obtain the best outcomes 
possible. 
LOHN Registry Feasibility Activity 
Concerning clinical trial feasibility activities, the low response rate by the clinical sites associated 
in a short deadline imposed by the sponsor demonstrated to be a challenging task to overcome. In 
order to overcome this situation, it was adopted a strategy of contact the clinical sites 
telephonically. More specifically, it was asked to talk to the investigators and if not possible to 
their secretary. It was requested new emails contacts for sending the feasibility questionnaire that 
were posteriorly added to the Lime Survey list of contacts. The deadline established to the 
sponsor was adapted and it was received more responses and feedback from the clinical sites. An 
important “tip” that I could learn from this process is that for contacting clinical trial centres for 
feasibility purposes it is very important to send the questionnaire not only for the investigator but 
for his secretary or study coordinators as well. Due to the elevated number of emails that an 
investigator could receive, it is very important to communicate with a larger number of clinical 
professionals involved in a trial. Also, I would like to point out an aspect that during my curricular 
internship I note that is very important – keep all information organised and easily traceable. 
During the follow-up of the responses to the feasibility were very important to keep all 
information recorded in different versions documents, and not substitute with more recent 
information. This way it is possible to consult information at different time points. 
The knowledge previously acquired during the Degree in Biomedical Sciences and Master in 
Pharmaceutical Medicine was reviewed and many topics became clearer. I could recognize that 
the structure and curricular units of this master course were essential to have a better 
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understanding of real-life activities developed within the implementation and coordination of a 
clinical research project.  
However, when starting my curricular internship I came across a reality that was totally unfamiliar 
to me.  The role of independent investigators in clinical research, their main difficulties faced 
when conducting clinical trials, possible sources of financing and relevant supporting 
infrastructures were all aspects that were not addressed in the Master Course.  
I suggest that in the future more importance is given to these topics in the curricular units. I think 
it would be of greater value have the presence of independent investigators in the curricular units 
for the future editions, and hear their experiences and evidences on how is to conduct IDCTs in 
Portugal. The vision of who conducts non-commercial interest clinical research is also important 
for our academic education. 
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5. Conclusions 
 
My training experience in a coordinating centre for clinical research allowed me to acquire a 
comprehensive understanding of a clinical research project’s lifecycle. I could assist in many 
activities required to design, implement, conduct and coordinate clinical trials. The experience of 
working in an aCRO was very challenging in many aspects since I could contact with a reality that 
was unfamiliar to me – the clinical research initiated by independent investigators. All these 
factors contribute for me to grow as a clinical research professional. 
This experience also allowed me to understand the central role of a project manager in the 
conduction of a clinical research project through its development stages. I understand that a 
project manager plays a pivotal role in a clinical dynamic environment, serving as an operational 
point person in the management of clinical studies. I could also understand that these 
professionals must have a strong scientific knowledge of project management and coordination 
and must possess solid problem-solving and leadership skills. They are crucial to motivate a 
clinical research team. 
After completing this training, I feel that I have grown as a clinical research professional. I 
improved personal skills and acquire professional competencies that, otherwise without this 
training experience would not be possible. Additionally, I consider to have contributed to the 
improvement of some activities carried out by 4C and UGQ with the implementation of Lime 
Survey as tool to send and manage questionnaires. 
 I am motivated to continue to develop my clinical research career with the certain that, in the 
future I would like to work in this area. 
I recognize that pharmaceutical medicine professionals may provide a very important 
contribution to any institution who wants to conduct clinical research. With a multidisciplinary 
background involving many clinical research subjects, I could integrate different knowledge in the 
daily-basis activities carried out during my training. 
In order to conclude this report I consider that the objectives initially established for my training 
were fully met.   
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Appendix I – Comparative Document between Survey Monkey 
and Lime Survey 
 
 
 
ELABORAÇÃO DE QUESTIONÁRIOS:  
SURVEYMONKEY E LIMESURVEY 
(COMPARAÇÃO DOS PROGRAMAS) 
 
 
 
 
 
 
DATA DA VERSÃO: 2012-11-01 
 
 
 
 
Documento de revisão 
 
Versão 
No. Data Descrição Elaborado por Revisto por 
0 2012-11-01 
Elaboração de questionários: 
SurveyMonkey e LimeSurvey. 
Comparação dos programas 
Ana Rita Ribeiro Sandrina Nunes 
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SurveyMonkey 
Características 
• Criação de questionários 
o 15 Tipos de questões 
• Personalização dos questionários 
o Nome, cores, temas, logotipo da empresa (este último necessita de actualização do 
plano de preços) 
• Gestão de repostas 
o Encerramento do questionário logo que alcançado o número de respostas desejado. 
É possível definir uma data e hora de corte, exigir uma senha e restringir as 
respostas a apenas uma por endereço IP 
o Incorporação do questionário no site da empresa 
•   Análise de resultados 
o Respostas recebidas em tempo real 
o Filtros de referência cruzada com os resultados 
o Exportação das respostas em múltiplos formatos (actualização de preços) 
 
Construção de um questionário 
• Novo questionário (título + categoria) 
• Utilizar um modelo de questionário  
• Utilizar um questionário existente 
 
 
 
 
 
Edição do questionário (opções) 
• Aparência 
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• Título e logotipo 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
• Páginas do questionário 
o Adição de novas páginas 
o Acrescentar randomização de página 
o Adicionar randomização de questão 
o Editar informação 
 Título da página (curto) 
 Breve descrição da finalidade da página 
o Adicionar questão 
 Texto 
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 Tipo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Opções de Design do questionário (opções) 
 Numeração da página e questão 
 Configurações da barra de progresso 
 Titulos de questionário/página 
 Idioma 
 Botões navegação 
 Realce de questão obrigatória 
 
Recursos GOLD 
 
 Exibir rodapé “Powered by SurveyMonkey” 
 Adicionar variáveis personalizadas (usar variáveis personalizadas para 
passar informações pré-coletadas ao questionário) 
 Adicionar cotas ao questionário (usar cotas para definir limites referentes 
ao numero de respostas que poderão ser recebidas por questões especificas 
do questionário)  
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MAIS:  
• Possibilidade de restaurar questões anteriormente eliminadas 
• Banco de questões previamente formuladas 
Divulgação do questionário 
 
 
Análise dos resultados 
• Exibir resumo 
• Procurar respostas 
• Filtrar respostas (é possível filtrar respostas por qualquer questão, mesmo as respostas 
abertas) 
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• Respostas de referência cruzada (tabulação cruzada das respostas com base em qualquer 
questão fechada) 
Plano de preços 
 
 
LimeSurvey 
Características 
• Criação de questionários 
o 20 Tipos de questões 
• Personalização dos questionários 
o Nome, cores, temas 
• Gestão de repostas 
o Encerramento do questionário logo que alcançada a data-limite de resposta.  
o Possibilidade de desativar o questionário antecipadamente 
o Possibilidades de os participantes guardarem o questionário e continuarem mais 
tarde. 
•   Análise de resultados 
o Análise gráfica e estatísticas básicas 
o Exportação de dados para ficheiros CVS, PDF, SPSS, R, QueXML e MS EXCEL 
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   Construção de um questionário 
• Título 
• Descrição do inquérito 
• Apresentação do questionário por páginas 
o Cada página pode conter um grupo de questões ou a totalidade das mesmas 
o Randomização de página e questão 
• Vários templates 
• 20 Tipos de questões  
• Adicionar questão 
o Tipo 
o Texto 
• Lógica de questões 
• Opções de design do questionário 
o Numeração de página e questão 
o Barra de progresso 
o Títulos de questionário/ página  
o Botões de navegação 
o Realce de questão obrigatória 
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Divulgação do questionário 
Divulgação por email – envio de convite para participar no questionário. 
 
 
Envio de um lembrete aos participantes que não acederam ou não completaram o estudo. 
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Análise dos resultados 
• Exibir resumo 
• Procurar respostas 
• Obter estatísticas a partir das respostas 
• Importar/ exportar ficheiros 
• Filtrar respostas 
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Plano de preços 
O LimeSurvey possibilita o envio gratuito de 25 questionários por mês, com um número ilimitado 
de perguntas. 
Comparação do SurveyMonkey e do LimeSurvey  
Plano básico  
Funcionalidades/ Programa Monkey Survey Lime Survey 
Nº questões por questionário 
 
10 Ilimitado 
Nº de questionários 
 
1001 
Outros planos: 
- 25€/mês 
- 300€/ano 
- 800€/ano 
25 (mês) 
Possibilidade de 
comprar mais respostas: 
- 100 respostas/10€ 
- 250 respostas/35€ 
- 1000 respostas/60€ 
- 2500 respostas/125€ 
- 5000 respostas/200€ 
Possibilidade de exportação de dados 
(excel, pdf, HTML) Não Sim 
   
Versão para impressão 
 
Não Sim 
Definição de data de encerramento do 
questionário Sim Sim 
 
Possibilidade de agrupar questionários 
personalizados 
Sim Sim 
 
No mesmo grupo, envio de questionários 
diferentes para o mesmo destinatário 
 
Sim Não 
Discriminação de respostas 
 
Sim Sim 
Personalização do email de convite 
 
Sim Sim 
Lógica de questão 
 
Não Sim 
Resposta única ao questionário 
 
Sim Sim 
Resumo de resultados Sim Sim 
NA – Não Aplicável 
                                                          
1
 Com uma conta básica, só serão exibidas as primeiras 100 respostas de cada questionário. 
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Anexos 
SurveyMonkey 
Resumo das respostas 
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Descrição das respostas de um participante 
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Descrição dos diferentes planos de preços 
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LimeSurvey 
Resumo das respostas – exemplo de uma pergunta do questionário 
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Descrição das respostas de um participante 
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Versão para impressão 
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Introduction 
LimeSurvey is available at https://www.limeservice.com/en/. You can create an acount by clicking 
on the “Click here To Sign Up” menu. Next, you must complete the required fields and accept the 
Terms and Conditions to finish your registration.  
After register, you can access your acount by the Login button . 
Now you can start creating surveys! 
A survey has three integral compenents, each of which must exist: 
• A survey name; 
• Al least one group; 
• At least one question. 
The survey name provides the unique title to a survey and becomes the handle to access various 
option settings that applyto the survey as a whole. Settings such as the welcome message on the 
opening screen, the description of the survey, contact information for the survey administrator and 
what the format the questions are to be asked. 
A survey requires each question to be a member of a group (and only that group). Dependig on the 
number of questions in the survey, groups can be used to define logical sections, common subject 
themes or possible pages on the screen. A group can have questions about a similar subject or 
simply to be setup as a manageable number of questions. 
A question group has a title and an optional descrption. You must have at least one group in each 
survey, even if you do not wish to divide the survey into multiple groups. 
Questions are the core of your survey. There is no real limit to the number of questions you can 
have in your survey or in a group. Questions include the actual question text as well as settings that 
determine what form of answer you will accept. You can also specify a short “help” explanation for 
each questions for each question and determine whether the question is mandatory (that is, must be 
answered) or optional.  
Creating Surveys 
The limesurvey tool presents horizontal tool bars to the survey creator in their web browser. These 
toolbars are the header of a window allowing interaction. 
Administrative Tool Bar 
The top toolbar is usually the administrative tool bar providing top level, global actions. one of the 
key items is the drop down list of surveys along with a Create New (survey) button . Both are 
on the top right side of the toolbar. 
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The  button provides you an online guide for Limesurvey. 
If the Administrative Tool Bar does not appear to be on top, click the home button  to get it 
back. The labelset  and Template  editors, available in this toolbar, are the only ones that can 
replace the Administrative Tool Bar. 
Survey Tool Bar 
Similar to before, one can click on the drop down list of question Groups or on the Create New 
(Group) button  toolbar. Either selection will bring up the question Group toolbar below the 
survey toolbar. 
 
In this menu you can also test a survey at any point while you are creating it, by choosing the Test 
Survey button . This allows you to check how the survey looks and feels before you actually 
initialize it. When testing a survey your responses will not be saved. 
 Survey settings 
There are several settings in Limesurvey that are edited by clicking the “Edit Survey Settings” icon 
 in the “Survey Properties” dropdown menu of the survey toolbar. All survey settings and 
functions are organized in tabs. It will be mentioned the most important features. 
• General 
o Base language- this sets the base language for the survey, once saved, it can not be 
change later; 
o Title – this is a brief descriptive name of the survey. By default, description is used 
in the invitation name; 
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o Welcome message – this allows you to enter a message that will display when a 
participant first logs into your survey; 
o End message – this allows you to enter a message that will display when a 
participant completes a survey; 
o Administrator – this is the name of the contact person who administers the survey; 
it will be included in emails sent out inviting participants to respond; 
o Admin email – this is the email address of the administrator and is used as the 
“reply to:” address on any emails sent; 
o Bounce email – this is the email address where a delivery error notification email 
should be sent. By default, this is the same as the administrator’s email address. 
• Presentation and navigation 
o Format  
 Question by question – the survey will display one question per page; 
 Group by group – the survey will display all questions in a group per page; 
 All in one – the survey will display all questions in one single page; 
o Templates 
o Show welcome screen – Yes/No. If yes, then the welcome message defined in Text 
Elements section will be displayed; 
o Show progress bar: Yes/No. allow the administrator to turn off the progress bar; 
o Show group name and/or group description 
 Show both (default); 
 Show group names only 
 Show group description only 
 Hide both 
o Show “No Answer”: Yes/No”. When Yes, the No Answer will be displayed as the 
default option for non-mandatory single-select questions. Be aware that if you 
switch this off, the participant won’t be able to unselect a chosen option in a non-
mandatory question; 
• Publication and access control 
o Start date/time – set this to some date if you want your survey to start on a special 
date. The survey will start on midnight of that day and only then will people be 
able to answer to it. 
o Expiry date/time – set this to some data if you want your survey to expire on a 
special date. This is the last date on which the public survey will let people 
participate; 
• Notification and data management 
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o Send a basic admin notification email to: and Send detailed admin notification 
email to: these fields will allow you to send notifications or surveys responses to 
additional email addresses once the survey is submitted 
o Date stamp? – This field allows you to determine whether the survey will 
datestamp all responses. If you choose Yes, then when a response is submitted, a 
field will be included in that response indicating the time and date that the response 
was made. 
o Save timings – if activate then on survey activation a separate table will be created 
where the timings for your questions will be saved, e.g. how long a user stays on 
on page during taking the survey. 
o Participant may save and resume later? – this setting allows a participant to save 
his response and resume to answer the survey at a later time 
• Tokens 
o Anonymized responses – this allows you to determine whether responses to your 
survey are matched up with information from your surveys tokens table, or kept 
“anonymous”. The default is “No”. if you choose “Yes” then your survey is set 
radically anonymize responses – there is really no way to connect answers and 
participants. 
o Allow editing of answers after completion? – Default: “No”. if you activate this 
setting the participants may return to his survey by clicking the invitation link even 
if he already submitted the survey. This only works for non-anonimyzed surveys 
Group Tool Bar 
Groups can be used to group questions in a survey. If you are going to have multiple groups, you 
should note that by default the survey questions will be displayed group by group. 
Groups can also include a “description”. This filed allows you to publish an explanatory note for 
any set of questions. If you add a description, it will be presented at the survey before commencing 
any of the questions of that group. If you do not include any text here, the public participants will 
simply move on to the first question in the group with no stop. 
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 Adding Questions 
Once you have created your groups, you can start adding questions within each group. Create a 
new question by clicking on the add icon  to add a fourth toolbar to now edit a Question. When 
adding a question, the options available are: 
• Question code – this code is only for quick identification for a question in export or for 
evaluation. Try to be consistent with your coding in this field. This field is normally not 
displayed to people taking the survey. 
• Question – this is the actual question being asked. There is no real limit lengh of the 
question here, however if you want to explain the question, leave that for the “Help” field. 
• Help – this is an optional field. It is useful if  a question needs some explanation, or you 
want to explain how it should be answered.. when you put text in this field, a “Question 
Mark” icon appears on the survey entry screen with the help text right beside. 
• Question type: this determines the type of reposnse the survey allows. View the section 
“Questions” of this manual. 
• Validation – this feature is available on all free text type questions (“Short Free Text”, 
“Long Free Text”, “Date” or “Numerical”). You can use standard Regular expressions in 
this field to validate the responses to the question, and if the responses don’t validate 
against this expression, the user will be prompted to ty again before they can progress. 
• Other? – depending upon you chosen “Question type” this option may appear. It allows 
you to specify that an “other” option be presented in some of th list question types. 
• Mandatory? – For all question types, except the text ones, this setting allows you to require 
users to answer the question, before they can move on the next question.  
• Relevance – this is the Boolean equation that specifies the conditions for this question. If it 
evaluates to true, the question is show; otherwise it is hidden and since it is irrelevant, data 
for that question is nulled in the database. 
You can also reorder questions by clicking on the Change Question Order icon in the group 
toolbar. You can change this order by sampling click on the “Up” and “Down” buttons. To preview 
a question click on the Preview Question icon  on the question bar. 
Various question types require you to add a list of answers options and/or subquestions. To add 
answers to one of these questions types click on the ”Add/Edit Answers for this Question” icon 
in question button bar. Similarly when adding questions, when adding answers you will be asked 
for: 
• Answer code; 
• Text – the answer/sub question that will be displayed; 
• Sort order – this determines the sort-order of the answers. You can use the “Up” and 
“Down” buttons next to each answer to change the position of that answer in the list. 
The existing question types are: 
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• Arrays 
An array allows you to create subquestions as your left hand headings along the y-axis of a table, 
and let participants respond with a series of possible answer options using those subquestions along 
the y-axis of the table.  Examples of uses for this type include multiple point choice scales and 
questions that require feedback on several aspects of a particular topic. The types of arrays 
available in Limesurvey are: 
o Array  
o Array (5 point choice) 
o Array (10 point choice) 
o Array (Yes/No/Uncertain) 
o Array (Increase/Same/Decrease) 
o Array by column 
o Array dual scale 
o Array (numbers) 
o Array (text) 
• Multiple choice questions 
Sometimes you want the participant to mark more than one option in the same question; this is 
achiving using checkboxes. The types of multiple choice questions available in Limesurvey 
are. 
o Multiple Choice; 
o Multiple Choice with comments. 
• Single choice questions 
Single choice questions are those where the participant can only pick a single predefined answer 
option. The types of sigle choice questions available are: 
o 5 point choice; 
o List (dropdown); 
o List with comment; 
o List (radio) 
• Text questions 
Limesurvey provides a number of possible variations of the standard text fields.all of these can be 
defined further using the “Advanced Question settings” which permit to restrict the number of 
characters as well as the size of the field. Types of text questions are: 
o Short free text; 
o Long free text; 
o Huge free text; 
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o Multiple short text. 
• Mask questions 
All questions where the input of answers is predifined are defined as “mask questions”. Examples 
are: 
o Date; 
o File upload; 
o Gender; 
o Language switch, 
o Numerical input; 
o Multiple numerical input; 
o Ranking; 
o Text display; 
o Yes/No; 
o Equation. 
Common Buttons 
In these nested toolbars are some common navigational buttons. There is an Edit button  to edit 
the object you selected. By default, you will be put in the editor if you create the object. There is a 
Delete button  to delete the object. For Groups and Questions, there is a Reorder button  to 
change the order the object appears in during the survey execution.  Finally, there is an Export 
button  to export a survey, question group or question that you can import back into another 
survey. Note that the Create button  also allows you to import a previously exported object. 
 
Finally, there are two to three small buttons to the far right  to minimize, maximize and 
close the window of a toolbar. The maximize button will take you back to the summary window of 
the currently selected object. 
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As seems natural, the window of the current toolbar is automatically minimized when you select a 
lower level object to edit. Only the current toolbar and its window can be closed. You can open a 
previous toolbar and window by clicking on its maximize button. You can jump around by 
selecting or creating a new object in another toolbar without having to close the currently open 
window first.  
Sending a Survey  
Activating a survey 
Once you are happy with the structure of your survey you can activate it by clicking on the 
“Activate Survey” icon . Activating a survey does a number of things: 
• It creates a separate database table to hold all survey responses, and creates for each 
possible answer to the survey a filed in the table; 
• It allows people to enter data into that table, and gives you access to other features for this 
survey; 
• It gives you access to the “tokens” feature. Once a survey is activated, the tokens button 
will be available; 
• If your survey is set to “not anonymous”, a tokens table will be created automatically. 
Before you activate a survey you should note that: 
• When the survey is initialized you can change the text for questions, answers, the survey, 
etc. but not the type of question or the type of answer.  
• You cannot add new questions or delete questions. Nor can you add answers to any of the 
array or multiple choice answers – however you can add answers to the basic list type 
questions. 
• If you deactivate (not expire) the survey, it will move the responses to a backup table and 
lose participation information but you will again be able to add new questions 
Once you have activated a survey and are receiving responses it is worthwhile considering the 
following: 
• Export the survey structure  immediately and save the .csv file on a safe place; 
• Regularly visit the “browse” screen  and export the received responses and keep c copy 
of the file. 
Participants - Tokens 
On many occasions you want to invite a group of people to participate on a survey, keep track of 
who has completed the survey, and ensure each person can only participate once. The tokens 
feature allows you to do the following: 
• Import a list of names and addresses for participants; 
• Generate a unique token number for each participant (invitation code); 
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• Send an email invitation to each person in your list who has not yet responded, by group or 
individually; 
• Track who from your list has responded; 
• Restrict access against people who have not got a token, and those with a token who have 
already responded; 
• Edit/change any details in your list; 
• Create email templates for invitations & reminders. 
Once the survey is switched to closed-access mode (you have enabled tokens for this survey), then 
only the people with a valid token code (not already used) can access the survey. 
Activate Tokens 
There are two ways to activate tokens: 
• After survey activation will be asked if you want to activate tokens 
 
• OR you can click on the tokens symbol  - even before the survey is activated. 
 
The token management tools 
 
 
After creating the tokens table you can click on the tokens icon to the token administration. The 
following section is a brief rundown of the menu options in the tokens screen: 
• Admin: returns to the main survey admin screen; 
• Summary: displays the complete list of participants in the tokens table (number of tokens, 
how many have been sent an invitation and how have responded).  
• Browse: displays the complete list of participants in the tokens table. From the browse 
screen you can edit or delete individual entries in the token table as well as perform a 
number of other useful functions; 
• Add new token entry: allows you to add an entry to the tokens table; 
• Add dummy token: allows you to add an entry to the tokens table; 
• Manage additional field attributes: allows you to add additional fields to the tokens table to 
store custom participant data; 
• Import from CSV: allows you to import information from a CSV file, 
• Import from LDAP: allows you to import information from an LDAP query; 
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• Export tokens to a CSV file: creates a standard CSV (comma delimited) file with a 
complete list of participants of your current tokens table; 
• Edit email templates: used to customize the templates used for the invitations, reminders, 
confirmations and registrations emails; 
• Send email invitation: sends bulk email invitations to all participants in the tokens table 
who have not already been sent an invitation; 
• Send reminder email: sends bulk email reminders to all participants in the tokens table who 
have not yet responded, but have been sent their first invitation, 
• Generate tokens: creates unique tokens for all individual entries in the tokens table that do 
not yet have one; 
• Drop token table: delete the token table and set the survey to open-access mode; 
Adding a Token 
A typical entry contains the following fields: 
 
 
• First and last name: … of the participant; 
• Email: the participant’s email address; 
• Email status: a field to keep track of bad emails. Marking this token with an email status 
other than “OK” will help skip this entry when sending invitation or reminder emails; 
• Token: this is the invitation code. It is usually generated by the “Generate tokens” button; 
• Language: if you to set the default language for this participant; 
• Invite sent: defaults to “N”, otherwise would contain the date when the invitation email 
was sent; 
• Reminder sent: defaults to “N”, otherwise would contain the date when the reminder was 
sent; 
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• Uses left: a counter of number of times the token can be used; 
• Valid from & valid until: you can sent a date/time range where this token would be allowed 
to use. You can leave this empty if you don’t want to limit participation time frame for 
certain uses. Note: if the user is answering the survey and the participation time ends then 
the user is locked out immediately and won’t be able to finish the survey. 
Create Dummy Tokens 
 
• Number of tokens: number of tokens to be added. Default is 100; 
• Token length: number of characters or length of token. Default is 15; 
• First and last name: … of participant; 
• Email: the participant’s email address; 
• Language: if you want to set the default language for this participant; 
• Uses left: a counter of number of times the token can be used; 
• Valid from & valid until: you can sent a date/time range where this token would be allowed 
to use. You can leave this empty if you don’t want to limit participation time frame for 
certain uses. Note: if the user is answering the survey and the participation time ends then 
the user is locked out immediately and won’t be able to finish the survey. 
Note that Name, email, language will be set to the same value for all dummy Tokens. 
Using the browser screen and editing tokens 
 
The browse screen will show you a list of all entries in the tokens table, as well as giving you some 
“action” buttons that can perform specific tasks for that individual entry. The top row of the table 
has three columns: the dialogue on the right gives options for displaying a number of records, and a 
starting point. In the middle is a search bar and the symbols on the left let you move backwards or 
forwards through your list. 
The second row of the table (see image below) includes various criteria to sort the entries and for 
each a green arrow that – if clicked – will refresh the screen showing the tokens ordered by that 
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criterion. The “Actions” column gives a list of specific tasks that can be performed on that 
individual entry: 
 
• Do the survey using the unique token of this entry; 
• Edit this entry; 
• Delete this entry; 
• Send an invitation/reminder to this survey entry; 
• If the survey is not anonymous, another button will appear, allowing you to view the 
response from this individual entry. 
Emailing 
 Field Names 
The following field names are allowed in invitation/reminder email templates and must be entered 
in the survey properties. When sending out the emails these field names will be already replaced in 
the preview of your invitation/reminder email. 
 
 
 
 
 
 
 
The following field names are allowed in invitation/reminder emails (subject and/or body) and will 
be replaced while sending out the emails: 
Field Name Description 
ADMINEMAIL Email of the Survey admin 
ADMINNAME Name of Survey Admin 
SURVEYNAME Title of your survey 
SURVEYDESCRIPTION Description of your survey 
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If your survey is NOT anonymous, the following field names are available to insert token data in 
survey text and javascript: 
 
 Send invitations 
 
You can skip tokens for which the email status is different from “OK”, by choosing the “bypass 
token with failing email addresses” option. 
 Participant opt-out 
When you use the OPTOUTURL tag in your invitation/reminder enail, your participants have the 
possibility to opt out of this particular survey by just clicking on the related URL in the email – so 
Field Name Description 
EMAIL Email of the recipiente 
FIRSTNAME First Name 
LASTNAME Last Name 
SURVEYURL The URL pointing to the survey start - if you are sending 
HTML emails this will be a fully linked HTML version 
OPTOUTURL The URL to deactivate sending of mail for this survey  - 
this will be a fully linked HTML version 
TOKEN Token to access the survey 
Field Name Description 
TOKEN:EMAIL Email of the recipient 
TOKEN:FIRSTNAME First Name 
TOKEN:LASTNAME Last Name 
TOKEN Token to access the survey 
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you do not harass them with reminder emails. A participant that opted out of your survey will have 
the email status “OptOut” set in the token. 
 Send reminders 
 
When sending reminders you can: 
• Bypass tokens with failing addresses; 
• Skip tokens for which an email has been recently sent; 
• Skip tokens for which a given number of emails have already been sent. 
Note: a reminder will only be send to tokens where the “completed” field is not “N” (this means the 
respondent has either not taken or has not completed the survey). 
 Confirmation email 
If you are using tokens and a participant fills out the survey, a confirmation email is sent to his/her 
email address. If you do not want this message to be sent, remove all content from the 
“Confirmation Email Subject” and “Confirmation Email” fields. 
Survey Results 
Closing a survey 
There are two ways for closing a survey: Expiry or deactivation. 
Expiry (edit the survey details and set an “Expiry Date”): 
• No results lost; 
• No respondent information lost; 
• Change of questions, groups and parameters is limited; 
• An expired survey is not accessible to participant (they only see a message that the survey 
has expired); 
• It is possible to perform statistics on responses inside limesurvey. 
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Deactivation (click on “deactivate this survey” in the administration panel) 
• All results lost; 
• All respondent information lost; 
• An expired survey is not accessible to a respondent (only a message appears that you are 
not permitted to see this survey); 
• All questions, groups and parameters are editable again. 
In case you accidentally deactivated you survey, it is important you do not change anything in the 
survey. Then you can activate your survey again. You go to the “Browse responses for this survey” 
menu. Click the “Important answers from a deactivated survey table” button. Next you can choose 
your survey table and click on the “import responses” button. 
Browse results 
When survey responses have been submitted, you will want to be able to view those responses, 
maybe edit some of them (or possibly delete some), export them, and get some information about 
the responses received so far, and so on. All of this is done through the browse function. 
When a survey is active, a browse  function will appear in the Survey information portion of the 
main admin screen. 
 
The main screen (Survey Summary) gives you the total number of responses recorded (full 
response and incomplete responses). Other options available in this screen are: 
• Admin: Return to the admin screen for surveys; 
• Survey summary: just show the total responses so far (initial screen); 
• Browse all: Display all the results to the survey (mote: the browse shows full descriptive 
question names, but only abbreviated answers); 
• Browse last 50: Display the last 50 responses to the survey, ordered from most recent to 
least recent; 
• Data entry: go to the data entry screen to add a new survey; 
• Printable version: printable version of the survey to be filled by hand; 
• Statistics: a simply method for filtering and getting summaries of responses; 
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• Export data: export all the responses to this survey to a Word, Excel or CSV file; 
• Backup survey X results: dump the table structure and contents to a standard CSV file. 
 
 Export data to application (Excel/.csv) 
On top of the browse responses page several export options are listed, beginning with “export to 
CSV/application”. 
 
 
When exporting results to an application there are several filter options which are separated into: 
• General  
o Set a range like export records X to Y; 
o Set to export all records, incomplete records only or incomplete records only; 
• Questions 
o Set how the heading should look like: Abbreviated heading, full headings or 
question codes; 
o Convert spaces in question text to underscores; 
• Answers 
o You can either export full answers or convert answers codes Y and N to a defined 
variable; 
• Format 
o Microsoft word; 
o Microsoft excel; 
o CSV file; 
o PDF; 
• Column Control 
o Set which answers should be exported; 
o Set which token data should be exported. This option is only available if your 
survey is not anonymous. 
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 View survey results by participant 
In order to view individual participant choices (and not the report regarding the whole survey), 
browse to: browse responses – display responses – click on one IDs in the left column. Participants 
can be identified either by token, name or IP address. 
 Editing and deleting responses 
When viewing your responses, you will be able to view a specific response by clicking on the ID 
number. From this point you can choose to Edit or Delete this response. 
Statistics 
 
 
The statistics feature allows you to filter your data and retrieve numbers and summaries of different 
fields from it. 
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When you click the “Get statistics” button you will be presented with a list of all available 
questions. For each question there is a checkbox that can be selected in order to show a summary 
table. To view the results for a question or questions, select the checkbox(es) at the top of the 
question(s) and then click “View stats”. Alternatively, to view the results for all available 
questions, check the “View summary of all available fields” box at the very top and then click 
“View stats”. 
You will then be given a “Results” table which will indicate the number of cases and a “Field 
Summary” table for each question selected which will summarize all possible answer in the 
question(s), their totals and percentages. 
 Filtering data 
Data can be filtered in several ways: 
• By survey completion – use the dropdown at the top to select Completed, Incompleted or 
All Records; 
• By ID – use the inputs to filter by ID number; 
• By text – you can search the responses to a free text question type (and similar types) by 
entering a text. 
Selecting “View stats” will then give you the Results table, indicating the number of responses 
matching your criteria, and a Field Summary table for each question selected which will summarize 
all possible answers in the question(s), their totals and their percentage. 
 
 Browsing/ exporting filtered results 
If you want to export the responses that match your criteria, click on the “export” button of the 
“Results” table. This will bring up the usual export screen, however when you export the results 
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you only receive the responses that match your criteria. Similarly, click on the browse to view the 
matching responses in the browse screen. 
Data entry 
 
Open the Data Entry Screen by clicking on the Data Entry Screen. This function is intended as a 
data entry system for paper based surveys. The Data Entry Screen is intended to be used when 
entering returned surveys on a mass basis and subsequently is designed to allow for keyboard based 
entry. 
 
